

# US Patent & Trademark Office

## Patent Public Search | Text View

United States Patent Application Publication

20250255953

Kind Code

A1

Publication Date

August 14, 2025

Inventor(s)

Kawaoka; Yoshihiro et al.

### RECOMBINANT INFLUENZA VIRUSES WITH STABILIZED HA FOR REPLICATION IN EGGS

#### Abstract

Modified influenza virus neuraminidases are described herein that improve viral replication, thus improving the yield of vaccine viruses. Expression of such modified neuraminidases by influenza virus may also stabilize co-expressed hemagglutinins so that the hemagglutinins do not undergo mutation.

**Inventors:** Kawaoka; Yoshihiro (Middleton, WI), Yamada; Shinya (Bunkyo-ku, JP), Chiba; Shiho (Madison, WI)

**Applicant:** The University of Tokyo (Tokyo, JP); Wisconsin Alumni Research Foundation (WARF) (Madison, WI)

**Family ID:** 1000008571810

**Appl. No.:** 19/067428

**Filed:** February 28, 2025

#### Related U.S. Application Data

parent US continuation 17546967 20211209 parent-grant-document US 12251436 child US 19067428

parent US continuation 16170321 20181025 parent-grant-document US 11197926 child US 17546967

us-provisional-application US 62577049 20171025

us-provisional-application US 62633400 20180221

#### Publication Classification

**Int. Cl.:** A61K39/145 (20060101); A61K9/00 (20060101); A61P31/16 (20060101); C07K14/005 (20060101); C12N7/00 (20060101); C12N9/24 (20060101); C12N15/63 (20060101)

## U.S. Cl.:

CPC     **A61K39/145** (20130101); **A61K9/0019** (20130101); **A61K9/0043** (20130101);  
**A61P31/16** (20180101); **C07K14/005** (20130101); **C12N7/00** (20130101); **C12N9/2402**  
(20130101); **C12N15/63** (20130101); C12N2760/16021 (20130101); C12N2760/16022  
(20130101); C12N2760/16034 (20130101); C12N2760/16051 (20130101);  
C12Y302/01018 (20130101)

---

## Background/Summary

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. application Ser. No. 17/546,967, filed Dec. 9, 2021, which is a continuation of U.S. application Ser. No. 16/170,321, filed Oct. 25, 2018, which application claims the benefit of the filing date of U.S. application Ser. No. 62/577,049, filed on Oct. 25, 2017, and U.S. application Ser. No. 62/633,400, filed on Feb. 21, 2018, the disclosures of which are incorporated by reference herein.

### INCORPORATION BY REFERENCE OF SEQUENCE LISTING

[0003] This application contains a Sequence Listing which has been submitted electronically in ST26 format and hereby incorporated by reference in its entirety. Said ST26 file, created on Feb. 26, 2025, is named 800101US3.xml and is 121,962 byte in size

### BACKGROUND

[0004] Influenza is a major respiratory disease in some mammals including horses and is responsible for substantial morbidity and economic losses each year. In addition, influenza virus infections can cause severe systemic disease in some avian species, leading to death. The segmented nature of the influenza virus genome allows for reassortment of segments during virus replication in cells infected with two or more influenza viruses. The reassortment of segments, combined with genetic mutation and drift, can give rise to a myriad of divergent strains of influenza virus over time. The new strains exhibit antigenic variation in their hemagglutinin (HA) and/or neuraminidase (NA) proteins, and in particular the gene coding for the HA protein has a high rate of variability. The predominant current practice for the prevention of flu is vaccination. Most commonly, inactivated virus vaccines are used. As the influenza HA protein is the major target antigen for the protective immune responses of a host to the virus and is highly variable, the isolation of influenza virus and the identification and characterization of the HA antigen in viruses associated with recent outbreaks is important for vaccine production. Based on prevalence and prediction, a vaccine is designed to stimulate a protective immune response against the predominant and expected influenza virus strains.

[0005] There are four general types of influenza viruses, Type A, Type B, Type C and Type D, which are defined by the absence of serological crossreactivity between their internal proteins. Influenza Type A viruses are further classified into subtypes based on antigenic and genetic differences of their glycoproteins, the HA and NA proteins. All the known HA and NA subtypes (H1 to H18 and N1 to N11) have been isolated from aquatic birds, which are thought to act as a natural reservoir for influenza.

[0006] Most influenza vaccines are produced in embryonated chicken eggs. However, the WHO-recommended influenza vaccine strains often do not replicate efficiently in embryonated chicken eggs, requiring serial passages in eggs in order to allow for adaptation of the virus. During adaptation and amplification in eggs, the hemagglutinin (HA) protein of influenza viruses often acquires egg-adapting mutations. These egg-adapting mutations in HA often alter the antigenicity of the viruses, resulting in vaccine viruses that are no longer optimally matched to the circulating

virus strains.

## SUMMARY

[0007] As described herein, an influenza virus was passaged 7 times in eggs (in triplicate) to study the mutations that occurred in the 6 non-immunogenic viral segments during adaptation.

Surprisingly, the virus acquired no HA mutations and instead had mutations in the NA, PB2, NP, and M1 proteins. The NA mutations were identical in all three experiments, and they included a deletion and 4 amino acid mutations. The NA mutations were tested alone and it was found that they, e.g., alone or in various combinations, were responsible for the effect, which permitted efficient growth in eggs without HA mutations.

[0008] The present disclosure thus relates to influenza mutations that prevent the acquisition of antigenicity-compromising mutations in the hemagglutinin (HA) segment of influenza virus during growth in eggs. The mutations in the neuraminidase (NA) protein of human influenza viruses were found to ‘stabilize’ the HA during egg-passages, e.g., in the presence of the mutations in NA, the HA protein did not acquire egg-adapting mutations. Those NA mutations may also increase the vaccine virus yield.

[0009] The disclosure provides isolated recombinant, e.g., reassortant, influenza viruses with selected amino acid residues or deletions at specified positions in NA. In one embodiment, the NA is selected to not encode a threonine at residue 32. In one embodiment, the NA is selected to not encode an aspartic acid at position 147. In one embodiment, the NA is selected to not encode an asparagine at residue 329. In one embodiment, the NA is selected to not encode a threonine at residue 329. In one embodiment, the NA is selected to not encode a histidine at residue 347. In one embodiment, the NA is selected to not encode an arginine or an asparagine at residue 347. In one embodiment, the NA is selected to not encode a NA having a threonine at position 148. In one embodiment, the NA is selected to not encode a NA having an aspartic acid at position 151. In one embodiment, the NA is selected to not encode a NA having an asparagine at position 245. In one embodiment, the NA is selected to not encode a NA having a glycine at position 346. In one embodiment, the NA is selected to have a deletion of one or more of residues 46 to 50. The numbering for NA is based on N2. In one embodiment, the disclosure provides an isolated recombinant reassortant influenza virus having six “internal” viral segments from a vaccine influenza virus, e.g., PR8UW, a NA viral segment with one or more of the specified residues at particular positions or a deletion of specified residues, or any combination thereof, and a HA viral segment, e.g., any of H1-H18, e.g., from a circulating influenza virus. Also provided are compositions comprising the recombinant influenza virus, pharmaceutical compositions such as vaccines.

[0010] Thus, for vaccine viruses that are to be grown or passaged in cells, e.g., in eggs, replacement of the residue at position 32, 147, 329, 347, or a deletion of one or more of residues 46 to 50, or any combination thereof, in NA, e.g., by mutation, or selection of a NA viral segment for a NA to not encode a threonine at residue 32, to not encode an aspartic acid at position 147, to not encode an asparagine at residue 329, to not encode a histidine at residue 347, or to have a deletion of one or more of residues 46 to 50, or any combination thereof, wherein the numbering is based on N2, may result in stabilization of HA and/or higher viral titers. In one embodiment, for vaccine viruses that are to be grown or passaged in cells, e.g., in eggs, replacement of the residue at position 147, 329, 347, or a deletion of one or more of residues 46 to 50, or any combination thereof, in NA, e.g., by mutation, or selection of a NA viral segment for a NA to not encode an aspartic acid at position 147, to not encode an asparagine at residue 329, to not encode a histidine at residue 347, 369, or any combination thereof, or optionally not encode a threonine at residue 369, or any combination thereof, wherein the numbering is based on N2, may result in stabilization of HA and/or higher viral titers. In one embodiment, for vaccine viruses that are to be grown or passaged in cells, e.g., in eggs, replacement of the residue at position 148, 151, 245, 346, or any combination thereof, in NA, e.g., by mutation, or selection of a NA viral segment for a NA to not

encode a threonine at residue 148, to not encode an aspartic acid at position 151, to not encode an asparagine at residue 245, to not encode a glycine at residue 346, or any combination thereof, wherein the numbering is based on N2, may result in stabilization of HA and/or higher viral titers. In one embodiment, for vaccine viruses that are to be grown or passaged in cells, e.g., in eggs, replacement of the residue at position 148, 151, 347, or any combination thereof, in NA, e.g., by mutation, or selection of a NA viral segment for a NA to not encode a threonine at residue 148, to not encode an aspartic acid at position 151, to not encode a histidine at residue 347, or any combination thereof, wherein the numbering is based on N2, may result in stabilization of HA and/or higher viral titers.

[0011] In one embodiment, the disclosure provides an isolated recombinant influenza virus comprising PA, PB1, PB2, NP, NS, M, and HA viral segments and a NA viral segment that encodes an NA selected to not encode a threonine at residue 32, to not encode an aspartic acid at position 147, to not encode an asparagine at residue 329, to not encode a histidine at residue 347, or to have a deletion of one or more of residues 46 to 50, or any combination thereof, wherein the numbering is based on N2, wherein the recombinant influenza virus has enhanced replication in avian eggs or has a reduction in HA mutations when grown in avian eggs relative to a corresponding influenza virus that has a NA that encodes a threonine at residue 32, does not have a deletion of residues 46 or 50, encodes an aspartic acid at position 147, encodes an asparagine at residue 329, encodes a histidine at residue 347, or any combination thereof. In one embodiment, the disclosure provides an isolated recombinant influenza virus comprising PA, PB1, PB2, NP, NS, M, and HA viral segments and a NA viral segment that encodes an NA selected to not encode a threonine at residue 148, to not encode an aspartic acid at position 151, to not encode an asparagine at residue 245, to not encode a glycine at residue 346, to not encode a histidine at residue 347, or any combination thereof, wherein the numbering is based on N2, wherein the recombinant influenza virus has enhanced replication in avian eggs or has a reduction in HA mutations when grown in avian eggs relative to a corresponding influenza virus that has a NA that encodes a threonine at residue 148, encodes an aspartic acid at position 151, encodes an asparagine at residue 245, encodes a glycine at residue 346, encodes a histidine at residue 347, or any combination thereof. In one embodiment, the isolated recombinant influenza virus is a reassortant. In one embodiment, the NA viral segment encodes a NA that has at least 80%, 85%, 90%, 95%, or 99% amino acid sequence identity to any one of SEQ ID Nos. 1-3, 30-38, 48-50, or 54. In one embodiment, the NA viral segment encodes a NA that has less than 100% amino acid sequence identity to SEQ ID NO:2 or SEQ ID NO:3. In one embodiment, the NA viral segment encodes a N2, N3, N7, or N9 and the positions in N3, N7, or N9 with the specified residue(s) correspond to the specified positions in N2. In one embodiment, the NA viral segment encodes a N1, N4, N5, N6, N8, N10 or N11 and the positions in N1, N4, N5, N6, N8, N10 or N11 with the specified residue(s) correspond to the specified positions in N2. In one embodiment, the residue at position 32 is A, I, G, or L. In one embodiment, the deletion is a deletion of residues 46 to 50. In one embodiment, the residue at position 147 is N or Q. In one embodiment, the residue at position 329 is D or E. In one embodiment, the residue at position 347 is Q, N, S, T, Y, C or W. In one embodiment, the HA is H1, H3, H5, H7, or H9. In one embodiment, the virus is an influenza A virus. In one embodiment, the PA, PB1, PB2, NP, M, and NS viral segments have at least 85% nucleic acid sequence identity to SEQ ID Nos. 24 to 29 or encode a polypeptide having at least 80%, 85%, 90%, 95%, or 99 amino acid sequence identity to a polypeptide encoded by SEQ ID Nos. 24 to 29 or 39-44. In one embodiment, the PB2 has I, A, L, or G at residue 147. In one embodiment, the virus is an influenza B virus.

[0012] Further provided is an isolated recombinant nucleic acid, e.g., a vector such as a viral vector, comprising a nucleic acid sequence that encodes an influenza virus NA selected to not encode a threonine at residue 32, to have a deletion of one or more of residues 46-50, to not encode an aspartic acid at position 147, to not encode an asparagine at residue 329, or to not encode a histidine at residue 347, or any combination thereof, wherein the numbering is based on N2. In one

embodiment, the isolated recombinant nucleic acid does not encode a threonine at residue 148, to not encode an aspartic acid at position 151, to not encode an asparagine at residue 245, to not encode a glycine at residue 346, or any combination thereof. In one embodiment, the NA has at least 95% amino acid sequence identity to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:48, or SEQ ID NO:49. In one embodiment, the NA has less than 100% amino acid sequence identity to SEQ ID NO:2 or SEQ ID NO:3. In one embodiment, the NA is a N2, N3, N7, or N9. In one embodiment, the NA is a N1, N4, N5, N6, N8, N10 or N11. In one embodiment, the residue at position 32 is A, I, G, or L. In one embodiment, the deletion is a deletion of residues 46 to 50. In one embodiment, the residue at position 147 is N or Q. In one embodiment, the residue at position 329 is D or E. In one embodiment, the residue at position 347 is Q, N, S, T, Y, C or W. In one embodiment, the residue at position 148 is K, R or H. In one embodiment, the residue at position 151 is E, N or Q. In one embodiment, the residue at position 245 is S, T, I, L, A, N, or V.

[0013] Also provided is a method to prepare influenza virus. The method includes contacting a cell with: a vector for vRNA production comprising a promoter operably linked to an influenza virus PA DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus PB1 DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus PB2 DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus HA DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus NP DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus NA DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus M DNA linked to a transcription termination sequence, and a vector for vRNA production comprising a promoter operably linked to an influenza virus NS DNA linked to a transcription termination sequence, wherein the PB1, PB2, PA, NP, NS, and M DNAs in the vectors for vRNA production are from one or more influenza vaccine virus isolates, wherein the NA DNA in the vector for vRNA production encodes an NA selected to not encode a threonine at residue 32, to not encode an aspartic acid at position 147, to not encode an asparagine at residue 329, to not encode a histidine at residue 347, to not encode a threonine at residue 148, to not encode an aspartic acid at position 151, to not encode an asparagine at residue 245, to not encode a glycine at residue 346, or to have a deletion of one or more of residues 46 to 50, or any combination thereof, wherein the numbering for NA residues is that for N2; and a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus PA, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus PB1, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus PB2, and a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus NP, and optionally comprising one or more of: a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus HA, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus NA, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus M1, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus M2, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus NS1, or a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus NS2; in an amount effective to yield infectious influenza virus. In one embodiment, the NA has at least 80%, 85%, 90%, 95%, or 99% amino acid sequence identity to SEQ ID NO:1 SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:48 or SEQ ID NO:49. In one embodiment, the NA has less than 100% amino acid sequence identity to SEQ ID NO:2 or SEQ ID NO:3. In one embodiment, the NA is N2, N3, N7, or N9. In

one embodiment, the NA is N1, N4, N5, N6, N8, N10 or N11. In one embodiment, the residue at position 32 is A, I, G, or L. In one embodiment, the deletion is a deletion of residues 46 to 50. In one embodiment, the residue at position 147 is N or Q. In one embodiment, the residue at position 329 is D or E. In one embodiment, the residue at position 346 is S, T, P, Y, W, A, N, I, L, or V. In one embodiment, the residue at position 347 is Q, N, S, T, Y, C or W. In one embodiment, the residue at position 148 is K, R or H. In one embodiment, the residue at position 151 is E, N or Q. In one embodiment, the residue at position 245 is S, T, I, L, A, N, or V.

[0014] In one embodiment, the HA is H1, H3, H5, H7, or H9. In one embodiment, the virus is an influenza A virus. In one embodiment, PA, PB1, PB2, NP, M, and NS viral segments have at least 85%, 85%, 90%, 95%, or 99% nucleic acid sequence identity to SEQ ID Nos. 24 to 29 or 39 to 44 or encode a polypeptide having at least 80%, 85%, 90%, 95%, or 99% amino acid sequence identity to a polypeptide encoded by SEQ ID Nos. 24 to 29 or 39 to 44. In one embodiment, PB2 has I, A, L, or G at residue 147. In one embodiment, HA is H2, H4, H5, H6, H8, or any of H10-H18. In one embodiment, the virus is an influenza B virus.

[0015] Further provided is a method of immunizing an avian or a mammal with a composition having an effective amount of the virus described herein. In one embodiment, the composition comprises at least one other different influenza virus. In one embodiment, the mammal is a human. In one embodiment, the composition is administered intranasally or via injection.

[0016] Thus, the invention provides a method to select for influenza viruses with enhanced replication in cell culture, e.g., in embryonated avian eggs. The method includes providing cells suitable for influenza vaccine production; serially culturing one or more influenza virus isolates in eggs; and isolating serially cultured virus with enhanced growth relative to the one or more isolates prior to serial culture. Also provided is a method to identify a NA that stabilizes HA and/or that confers altered growth of a recombinant influenza virus, e.g., in eggs. The method includes introducing one or more substitutions or deletions as described herein into a NA viral segment to yield a mutant NA viral segment; and optionally identifying whether the mutant NA viral segment, when present in a replication competent recombinant influenza virus, results in enhanced replication of the recombinant influenza virus in eggs and optionally inhibits HA mutations, relative to a corresponding replication competent influenza virus without the one or more substitutions and/or deletions in NA.

[0017] In one embodiment, the disclosure provides isolated influenza type A virus with a characteristic residue(s) and/or deletion, or a combination thereof, in NA described herein. In one embodiment, the isolated influenza type A virus with a characteristic residue(s) and/or deletion, or a combination thereof, has an NA amino acid sequence with at least 80%, e.g., 90%, 92%, 95%, 97% or 99%, including any integer between 80 and 99, contiguous amino acid sequence identity to a polypeptide encoded by one of SEQ ID NOs:1, 2, 3, or 30-38. In one embodiment, the isolated influenza type A virus of the invention with a characteristic residue(s) and/or deletion, or a combination thereof, has an HA from any one of subtypes 1-18 of HA. In one embodiment the characteristic residue is a conservative substitution, e.g., relative to SEQ ID NO:2 or SEQ ID NO:3. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine and tryptophan; a group of amino acids having basic side chains is lysine, arginine and histidine; and a group of amino acids having sulfur-containing side chain is cysteine and methionine. In one embodiment, conservative amino acid substitution groups are: threonine-valine-leucine-isoleucine-alanine; phenylalanine-tyrosine; lysine-arginine; alanine-valine; glutamic-aspartic; and asparagine-glutamine.

[0018] In one embodiment, a mutation is introduced into a NA viral segment of an influenza virus

isolate, e.g., via recombinant DNA techniques including site-specific mutagenesis, or replacing a portion of the NA coding sequence with a portion that includes the characteristic residue(s) or deletion. In one embodiment, a NA viral segment with a characteristic residue and/or deletion described herein is combined with a HA segment, and internal viral segments of an influenza vaccine virus.

[0019] The disclosure provides a plurality of influenza virus vectors of the invention, e.g., those useful to prepare reassortant viruses including 6:1:1 reassortants, 6:2 reassortants and 7:1 reassortants. A 6:1:1 reassortant is an influenza virus with 6 internal viral segments from a vaccine virus, a HA viral segment that is from a different (second) viral isolate than the vaccine virus, and a NA viral segment with a characteristic residue(s) and/or deletion, or a combination thereof, as described herein, which is from a different viral source than the HA segment and the vaccine virus; a 6:2 reassortant is an influenza virus with 6 internal viral segments from a vaccine virus, and a NA viral segment having a characteristic residue(s) and/or deletion, or a combination thereof, which segment is from the same source as the HA segment, and a HA viral segment from a different viral isolate than the vaccine virus; and a 7:1 reassortant, in one embodiment, is an influenza virus with 6 internal viral segments and a HA segment from a vaccine virus, and a NA segment that is modified to include the characteristic residue(s) and/or deletion, or a combination thereof, which NA segment is from a different viral source than the vaccine virus.

[0020] In one embodiment of the invention, the plurality includes vectors for vRNA production selected from a vector comprising a promoter operably linked to an influenza virus PA DNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus PB1 DNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus PB2 DNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus HA DNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus NP DNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus NA DNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus M DNA linked to a transcription termination sequence, and a vector comprising a promoter operably linked to an influenza virus NS DNA linked to a transcription termination sequence. In one embodiment, the DNAs for vRNA production of PB1, PB2, PA, NP, M, and NS, have sequences from an influenza virus that replicates to high titers in cultured mammalian cells such as Vero cells, MDCK cells, or PER.C6® cells, or embryonated eggs, and/or from a vaccine virus, e.g., one that does not cause significant disease in humans. The DNA for vRNA production of NA may be from any NA, e.g., any of N1-N9, and the DNA for vRNA production of HA may be from any HA, e.g., H1-H18. In one embodiment, the DNAs for vRNA production may be for an influenza B or C virus. For example, the DNAs for vRNA production include influenza B virus PA, PB1, PB2, NP, NS, and M or influenza B virus PA, PB1, PB2, NP, NS, M, and NA, wherein the vRNA for NA has a NA with a characteristic residue and/or deletion as described herein. The DNAs for vRNA production of NA and HA may be from different strains or isolates (6:1:1 reassortants) or from the same strain or isolate (6:2 reassortants), or the NA or HA may be from the same strain or isolate as that for the internal genes (7:1 reassortant). The plurality also includes vectors for mRNA production selected from a vector encoding influenza virus PA, a vector encoding influenza virus PB1, a vector encoding influenza virus PB2, and a vector encoding influenza virus NP, and optionally one or more vectors encoding NP, NS, M, e.g., M1 and M2, HA or NA. The vectors encoding viral proteins may further include a transcription termination sequence.

[0021] Viruses that may provide the internal genes for reassortants within the scope of the invention include viruses that have high titers, e.g., titers of at least about  $10^{5.5}$  PFU/mL, e.g., at least  $10^{6.5}$  PFU/mL,  $10^{7.5}$  PFU/mL or  $10^{8.5}$  PFU/mL; high titers in embryonated eggs, e.g., titers of at least about  $10^{7.5}$  EID<sub>50</sub>/mL, e.g., at least  $10^{8.5}$  EID<sub>50</sub>/mL,  $10^{9.5}$

EID.sub.50/mL or 10.sup.10 EID.sub.50/mL; high titers in MDCK cells, e.g., titers of at least about 10.sup.7 PFU/mL, e.g., at least 10.sup.8 PFU/mL, or high titers in two of more of those host cells. [0022] Other reassortants with internal genes from other PR8 isolates or vaccine viruses may be employed in recombinant reassortant viruses.

[0023] In one embodiment, the DNAs for the internal genes for PB1, PB2, PA, NP, M, and NS encode proteins with substantially the same activity as a corresponding polypeptide encoded by one of SEQ ID NOs:24-29 or 39 to 44. As used herein, "substantially the same activity" includes an activity that is about 0.1%, 1%, 10%, 30%, 50%, 90%, e.g., up to 100% or more, or detectable protein level that is about 80%, 90% or more, the activity or protein level, respectively, of the corresponding full-length polypeptide. In one embodiment, the nucleic acid a sequence encoding a polypeptide which is substantially the same as, e.g., having at least 80%, e.g., 90%, 92%, 95%, 97% or 99%, including any integer between 80 and 99, contiguous amino acid sequence identity to, a polypeptide encoded by one of SEQ ID NOs:24-29 or 39 to 44. In one embodiment, the isolated and/or purified nucleic acid molecule comprises a nucleotide sequence which is substantially the same as, e.g., having at least 50%, e.g., 60%, 70%, 80% or 90%, including any integer between 50 and 100, or more contiguous nucleic acid sequence identity to one of SEQ ID NOs:24-29 and, in one embodiment, also encodes a polypeptide having at least 80%, e.g., 90%, 92%, 95%, 97% or 99%, including any integer between 80 and 99, contiguous amino acid sequence identity to a polypeptide encoded by one of SEQ ID NOs:24-29 or 39 to 44. In one embodiment, the influenza virus polypeptide has one or more, for instance, 2, 5, 10, 15, 20 or more, conservative amino acids substitutions, e.g., conservative substitutions of up to 10% or 20% of the residues, relative to a polypeptide encoded by one of SEQ ID NOs:24-29 or 39 to 44. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine and tryptophan; a group of amino acids having basic side chains is lysine, arginine and histidine; and a group of amino acids having sulfur-containing side chain is cysteine and methionine. In one embodiment, conservative amino acid substitution groups are: valine-leucine-isoleucine; phenylalanine-tyrosine; lysine-arginine; alanine-valine; glutamic-aspartic; and asparagine-glutamine. In one embodiment, the influenza virus polypeptide has one or more, for instance, 2, 3 or 4, nonconservative amino acid substitutions, relative to a polypeptide encoded by one of SEQ ID NOs:24-29.

[0024] In one embodiment, the nucleic acid a sequence encoding a NA polypeptide which is substantially the same as, e.g., having at least 80%, e.g., 90%, 92%, 95%, 97% or 99%, including any integer between 80 and 99, contiguous amino acid sequence identity to, a polypeptide encoded by one of SEQ ID NOs:1, 3, 30-35, 48-49, or one of Accession Nos. ACP41107.1 (N1) (SEQ ID NO:36) AIK26357.1 (N7) (SEQ ID NO:37), ALH21372.1 (N9) (SEQ ID NO:45), or BAK86313.1 (N2) (SEQ ID NO:50), the sequences of which are incorporated by reference herein. In one embodiment, the isolated and/or purified nucleic acid molecule encodes a polypeptide having at least 80%, e.g., 90%, 92%, 95%, 97% or 99%, including any integer between 80 and 99, contiguous amino acid sequence identity to a polypeptide encoded by SEQ ID NOs:1, 3, 30-35, 48-49, or one of Accession Nos. ACP41107.1 (N1) AIK26357.1 (N7), ALH21372.1 (N9), or BAK86313.1 (N2), the sequences of which are incorporated by reference herein. In one embodiment, the influenza virus polypeptide has one or more, for instance, 2, 5, 10, 15, 20 or more, conservative amino acids substitutions, e.g., conservative substitutions of up to 10% or 20% of the residues, relative to a polypeptide encoded by one of SEQ ID NOs:1, 3, 30-35, 48-49, or one of Accession Nos. ACP41107.1 (N1) AIK26357.1 (N7), ALH21372.1 (N9), or BAK86313.1 (N2), the sequences of which are incorporated by reference herein. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of



amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine and tryptophan; a group of amino acids having basic side chains is lysine, arginine and histidine; and a group of amino acids having sulfur-containing side chain is cysteine and methionine. In one embodiment, conservative amino acid substitution groups are: valine-leucine-isoleucine; phenylalanine-tyrosine; lysine-arginine; alanine-valine; glutamic-aspartic; and asparagine-glutamine. In one embodiment, the influenza virus polypeptide has one or more, for instance, 2, 3 or 4, nonconservative amino acid substitutions, relative to a polypeptide encoded by one of SEQ ID NOs:1, 3, 30-35, 48-49, or one of Accession Nos. ACP41107.1 (N1) AIK26357.1 (N7), ALH21372.1 (N9), or BAK86313.1 (N2), the sequences of which are incorporated by reference herein.

[0025] The invention thus includes the use of isolated and purified vectors or plasmids, which express or encode influenza virus proteins, or express or encode influenza vRNA, both native and recombinant vRNA. The vectors comprise influenza cDNA, e.g., influenza A (e.g., any influenza A gene including any of the 18 HA or 11 NA subtypes), B or C DNA (see Fields *Virology* (Fields et al. (eds.), Lippincott, Williams and Wickens (2013), which is specifically incorporated by reference herein). Any suitable promoter or transcription termination sequence may be employed to express a protein or peptide, e.g., a viral protein or peptide, a protein or peptide of a nonviral pathogen, or a therapeutic protein or peptide.

[0026] A composition or plurality of vectors of the invention may also comprise a heterologous gene or open reading frame of interest, e.g., a foreign gene encoding an immunogenic peptide or protein useful as a vaccine or in gene replacement, for instance may encode an epitope useful in a cancer therapy or vaccine, or a peptide or polypeptide useful in gene therapy. When preparing virus, the vector or plasmid comprising the gene or cDNA of interest may substitute for a vector or plasmid for an influenza viral gene or may be in addition to vectors or plasmids for all influenza viral genes. Thus, another embodiment of the invention comprises a composition or plurality of vectors as described above in which one of the vectors is replaced with, or further comprises, 5' influenza virus sequences optionally including 5' influenza virus coding sequences or a portion thereof, linked to a desired nucleic acid sequence, e.g., a desired cDNA, linked to 3' influenza virus sequences optionally including 3' influenza virus coding sequences or a portion thereof. In one embodiment, the desired nucleic acid sequence such as a cDNA is in an antisense (antigenomic) orientation. The introduction of such a vector in conjunction with the other vectors described above to a host cell permissive for influenza virus replication results in recombinant virus comprising vRNA corresponding to the heterologous sequences of the vector.

[0027] The promoter in a vector for vRNA production may be a RNA polymerase I promoter, a RNA polymerase II promoter, a RNA polymerase III promoter, a T7 promoter, or a T3 promoter, and optionally the vector comprises a transcription termination sequence such as a RNA polymerase I transcription termination sequence, a RNA polymerase II transcription termination sequence, a RNA polymerase III transcription termination sequence, or a ribozyme. Ribozymes within the scope of the invention include, but are not limited to, tetrahymena ribozymes, RNase P, hammerhead ribozymes, hairpin ribozymes, hepatitis ribozyme, as well as synthetic ribozymes. In one embodiment, the RNA polymerase I promoter is a human RNA polymerase I promoter.

[0028] The promoter or transcription termination sequence in a vRNA or virus protein expression vector may be the same or different relative to the promoter or any other vector. In one embodiment, the vector or plasmid which expresses influenza vRNA comprises a promoter suitable for expression in at least one particular host cell, e.g., avian or mammalian host cells such as canine, feline, equine, bovine, ovine, or primate cells including human cells, or for expression in more than one host.

[0029] In one embodiment, at least one vector for vRNA comprises a RNA polymerase II promoter

linked to a ribozyme sequence linked to viral coding sequences linked to another ribozyme sequences, optionally linked to a RNA polymerase II transcription termination sequence. In one embodiment, at least 2, e.g., 3, 4, 5, 6, 7 or 8, vectors for vRNA production comprise a RNA polymerase II promoter, a first ribozyme sequence, which is 5' to a sequence corresponding to viral sequences including viral coding sequences, which is 5' to a second ribozyme sequence, which is 5' to a transcription termination sequence. Each RNA polymerase II promoter in each vRNA vector may be the same or different as the RNA polymerase II promoter in any other vRNA vector. Similarly, each ribozyme sequence in each vRNA vector may be the same or different as the ribozyme sequences in any other vRNA vector. In one embodiment, the ribozyme sequences in a single vector are not the same.

[0030] In one embodiment, at least one vector comprises sequences corresponding to those encoding PB1, PB2, PA, NP, M, or NS, or a portion thereof, having substantially the same activity as a corresponding polypeptide encoded by one of SEQ ID NOs:24-29 or 39 to 44, e.g., a sequence encoding a polypeptide with at least 80%, e.g., 85%, 90%, 92%, 95%, 98%, 99% or 100%, including any integer between 80 and 100, amino acid identity to a polypeptide encoded by one of SEQ ID NOs:24-29. Optionally, two vectors may be employed in place of the vector comprising a promoter operably linked to an influenza virus M cDNA linked to a transcription termination sequence, e.g., a vector comprising a promoter operably linked to an influenza virus M1 cDNA linked to a transcription termination sequence and a vector comprising a promoter operably linked to an influenza virus M2 cDNA linked to a transcription termination sequence.

[0031] A plurality of the vectors of the invention may be physically linked or each vector may be present on an individual plasmid or other, e.g., linear, nucleic acid delivery vehicle. In one embodiment, each vRNA production vector is on a separate plasmid. In one embodiment, each mRNA production vector is on a separate plasmid.

[0032] The invention also provides a method to prepare influenza virus. The method comprises contacting a cell with a plurality of the vectors of the invention, e.g., sequentially or simultaneously, in an amount effective to yield infectious influenza virus. The invention also includes isolating virus from a cell contacted with the plurality of vectors. Thus, the invention further provides isolated virus, as well as a host cell contacted with the plurality of vectors or virus of the invention. In another embodiment, the invention includes contacting the cell with one or more vectors, either vRNA or protein production vectors, prior to other vectors, either vRNA or protein production vectors. In one embodiment, the promoter for vRNA vectors employed in the method is a RNA polymerase I promoter, a RNA polymerase II promoter, a RNA polymerase III promoter, a T3 promoter or a T7 promoter. In one embodiment, the RNA polymerase I promoter is a human RNA polymerase I promoter. In one embodiment, each vRNA vector employed in the method is on a separate plasmid. In one embodiment, the vRNA vectors employed in the method are on one plasmid or on two or three different plasmids. In one embodiment, each mRNA vector employed in the method is on a separate plasmid. In one embodiment, the mRNA vectors for PA, PB1, PB2 and NP employed in the method are on one plasmid or on two or three different plasmids.

[0033] The methods of producing virus described herein, which do not require helper virus infection, are useful in viral mutagenesis studies, and in the production of vaccines (e.g., for AIDS, influenza, hepatitis B, hepatitis C, rhinovirus, filoviruses, malaria, herpes, and foot and mouth disease) and gene therapy vectors (e.g., for cancer, AIDS, adenosine deaminase, muscular dystrophy, ornithine transcarbamylase deficiency and central nervous system tumors). Thus, a virus for use in medical therapy (e.g., for a vaccine or gene therapy) is provided.

[0034] The invention also provides isolated viral polypeptides, and methods of preparing and using recombinant virus of the invention. The methods include administering to a host organism, e.g., a mammal, an effective amount of the influenza virus of the invention, e.g., an inactivated virus preparation, optionally in combination with an adjuvant and/or a carrier, e.g., in an amount

effectively to prevent or ameliorate infection of an animal such as a mammal by that virus or an antigenically closely related virus. In one embodiment, the virus is administered intramuscularly while in another embodiment, the virus is administered intranasally. In some dosing protocols, all doses may be administered intramuscularly or intranasally, while in others a combination of intramuscular and intranasal administration is employed. The vaccine may further contain other isolates of influenza virus including recombinant influenza virus, other pathogen(s), additional biological agents or microbial components, e.g., to form a multivalent vaccine. In one embodiment, intranasal vaccination, for instance containing with inactivated influenza virus, and a mucosal adjuvant may induce virus-specific IgA and neutralizing antibody in the nasopharynx as well as serum IgG.

[0035] The influenza virus of the invention may employed with other anti-virals, e.g., amantadine, rimantadine, and/or neuraminidase inhibitors, e.g., may be administered separately in conjunction with those anti-virals, for instance, administered before, during and/or after.

[0036] Thus, the modified neuraminidase comprises at least one, or at least two, or at least three modifications, wherein the modification comprise one or more amino acids within positions 29-35, one or more amino acids within positions 44-52, one or more amino acids within positions 144-154, one or more amino acid positions within 240-250, one or more amino acids within positions 326-333, one or more amino acid positions within 344-350, one or more amino acid positions within 365-375, or combinations thereof, wherein the numbering is that for N2. In one embodiment, the NA comprises a deletion of at least one proline, asparagine, glutamine, valine, or a combination of a proline, one or more asparagine(s), a glutamine, and a valine within positions 44-52; a substitution (replacement) of a threonine within positions 29-35; a substitution (replacement) of an threonine or an aspartic acid within positions 145-155; a substitution (replacement) of an asparagine within positions 240 to 250 or 326-333; a substitution (replacement) of a histidine within positions 345-350; or a combination thereof.

---

## Description

### BRIEF DESCRIPTION OF FIGURES

[0037] FIG. 1. Nucleotide sequences for the viral segments of A/Yokohama/2017/2003 (SEQ ID Nos. 4-11), and amino acid sequence of the NA of A/Yokohama/2017/2003 (SEQ ID NO:3).

[0038] FIG. 2. Amino acid sequence for the NA of A/Saitama/103/2014 (SEQ ID NO:2)

[0039] FIG. 3. Nucleotide sequence of NA viral segment (SEQ ID NO:12) and amino acid sequences for NA of mutant of A/Yokohama/2017/2003 (SEQ ID NO:1), and nucleotide sequence of other viral segments of the mutant (SEQ ID Nos.12-21)

[0040] FIG. 4. Graph showing titers in eggs of various reassortants with the PB2, M, NA and NP segments of mutant and wild-type A/Yokohama/2017/2003. Virus inoculation:  $2 \times 10^{3.3}$  pfu/egg into allantoic fluid, 72 h incubation at 37° C.

[0041] FIG. 5. Locations of the NA mutations on the 3D structure of N2 NA.

[0042] FIG. 6. Graph showing titers in eggs for recombinant viruses with specific mutations found in the mutant of A/Yokohama/2017/2003 (“Y2017-M3L4”). Virus inoculation:  $2 \times 10^{3.3}$  pfu/egg into allantoic fluid, 72 h incubation at 37° C.

[0043] FIG. 7. Graph of virus titer in eggs for reassortants with two different backbones (PA, PB1, PB2, NP, NS and M) and two different HA and NA combinations (e.g., PB2-I504V, PB1-M40L/G180W, PA-R401K, NP-I116L, NS1-A30P/R118K; and NA of Y2017-M3L4 contains mutations; NA-T32A, D147N, N329D, H347Q and deletion of 46-50aa). Virus inoculation:  $2 \times 10^{3.3}$  pfu/egg into allantoic fluid, 72 h incubation at 37° C.

[0044] FIG. 8. Amino acid sequence comparison of Yokohama/2017/2003 NA wild-type (SEQ ID NO:3) and Y2017-M3L4 (SEQ ID NO:1).

[0045] FIG. **9**. Exemplary NA sequences for N3, N4, N6, N7, N8, and N9 (SEQ ID Nos. 30-35).  
[0046] FIG. **10**. Exemplary sequences for the internal viral segments for a master vaccine strain (SEQ ID Nos. 39-44).  
[0047] FIG. **11**. Exemplary NA sequences (SEQ ID Nos:51-54).  
[0048] FIG. **12**. Titers in eggs for various NA mutants.  
[0049] FIG. **13**. Titers of HK4801HA, Y2017-M3L4NA and HY-PR8 (PB2 C4U, I504V; PB1 C4U, M40L/G180W; PA C4U, R401K; NP I116L; NS A30P/R118K) and analyses for HA mutations in infected eggs over time.  
[0050] FIG. **14** shows data for viruses passaged in eggs that had certain NA mutants but did not result in substitutions in HA.  
[0051] FIG. **15** is a schematic of the positions of certain NA residues.  
[0052] FIG. **16** is a schematic of the positions of certain NA residues.  
[0053] FIG. **17** shows virus titers for egg passaged isolates (HK4801NA (T148K, D151E, H347G, and T369K)) conferred efficient replication in the allantoic cavity to viruses possessing either HK4801HA or Singapore0019 HA (HY-PR8 backbone).  
[0054] FIG. **18** shows egg titers for different combinations of selected residues at positions 153, 329, 347, and 369 in NA.  
[0055] FIG. **19** summarizes virus titers and HA status over time (HK4801HA, Y2017-M3L4NA and HY-PR8 (PB2 C4U, I504V; PB1 C4U, M40L/G180W; PA C4U, R401K; NP I116L; NS A30P/R118K)).  
[0056] FIG. **20** summarizes virus titers and HA status for viruses with different NAs.  
[0057] FIG. **21** provides inoculation and harvested virus titers in allantoic passages (HA-K189E/N158K/A212T mutant virus).  
[0058] FIG. **22** shows detection of HA status after multiple passages.  
[0059] FIG. **23** shows egg titers for viruses with different NAs.  
[0060] FIG. **24** is an enlarged view of the NA activity center. Most egg-adapted mutations are located in/around the NA active site.

## DETAILED DESCRIPTION

### Definitions

[0061] As used herein, the term “isolated” refers to in vitro preparation and/or isolation of a nucleic acid molecule, e.g., vector or plasmid, peptide or polypeptide (protein), or virus of the invention, so that it is not associated with in vivo substances, or is substantially purified from in vitro substances. An isolated virus preparation is generally obtained by in vitro culture and propagation, and/or via passage in eggs, and is substantially free from other infectious agents.  
[0062] As used herein, “substantially purified” means the object species is the predominant species, e.g., on a molar basis it is more abundant than any other individual species in a composition, and preferably is at least about 80% of the species present, and optionally 90% or greater, e.g., 95%, 98%, 99% or more, of the species present in the composition.  
[0063] As used herein, “substantially free” means below the level of detection for a particular infectious agent using standard detection methods for that agent.  
[0064] A “recombinant” virus is one which has been manipulated in vitro, e.g., using recombinant DNA techniques, to introduce changes to the viral genome. Reassortant viruses can be prepared by recombinant or nonrecombinant techniques.  
[0065] As used herein, the term “recombinant nucleic acid” or “recombinant DNA sequence or segment” refers to a nucleic acid, e.g., to DNA, that has been derived or isolated from a source, that may be subsequently chemically altered in vitro, so that its sequence is not naturally occurring, or corresponds to naturally occurring sequences that are not positioned as they would be positioned in the native genome. An example of DNA “derived” from a source, would be a DNA sequence that is identified as a useful fragment, and which is then chemically synthesized in essentially pure form. An example of such DNA “isolated” from a source would be a useful DNA sequence that is excised

or removed from said source by chemical means, e.g., by the use of restriction endonucleases, so that it can be further manipulated, e.g., amplified, for use in the disclosure, by the methodology of genetic engineering.

[0066] As used herein, a “heterologous” influenza virus gene or viral segment is from an influenza virus source that is different than a majority of the other influenza viral genes or viral segments in a recombinant, e.g., reassortant, influenza virus.

[0067] The terms “isolated polypeptide”, “isolated peptide” or “isolated protein” include a polypeptide, peptide or protein encoded by cDNA or recombinant RNA including one of synthetic origin, or some combination thereof.

[0068] The term “recombinant protein” or “recombinant polypeptide” as used herein refers to a protein molecule expressed from a recombinant DNA molecule. In contrast, the term “native protein” is used herein to indicate a protein isolated from a naturally occurring (i.e., a nonrecombinant) source. Molecular biological techniques may be used to produce a recombinant form of a protein with identical properties as compared to the native form of the protein.

[0069] Methods of alignment of sequences for comparison are well known in the art. Thus, the determination of percent identity between any two sequences can be accomplished using a mathematical algorithm.

[0070] Computer implementations of these mathematical algorithms can be utilized for comparison of sequences to determine sequence identity. Alignments using these programs can be performed using the default parameters. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). The algorithm may involve first identifying high scoring sequence pairs (HSPs) by identifying short words of length  $W$  in the query sequence, which either match or satisfy some positive-valued threshold score  $T$  when aligned with a word of the same length in a database sequence.  $T$  is referred to as the neighborhood word score threshold. These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters  $M$  (reward score for a pair of matching residues; always  $>0$ ) and  $N$  (penalty score for mismatching residues; always  $<0$ ). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when the cumulative alignment score falls off by the quantity  $X$  from its maximum achieved value, the cumulative score goes to zero or below due to the accumulation of one or more negative-scoring residue alignments, or the end of either sequence is reached.

[0071] In addition to calculating percent sequence identity, the BLAST algorithm may also perform a statistical analysis of the similarity between two sequences. One measure of similarity provided by the BLAST algorithm may be the smallest sum probability ( $P(N)$ ), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a test nucleic acid sequence is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid sequence to the reference nucleic acid sequence is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

[0072] The BLASTN program (for nucleotide sequences) may use as defaults a wordlength ( $W$ ) of 11, an expectation ( $E$ ) of 10, a cutoff of 100,  $M=5$ ,  $N=-4$ , and a comparison of both strands. For amino acid sequences, the BLASTP program may use as defaults a wordlength ( $W$ ) of 3, an expectation ( $E$ ) of 10, and the BLOSUM62 scoring matrix. See <http://www.ncbi.nlm.nih.gov>. Alignment may also be performed manually by inspection.

[0073] For sequence comparison, typically one sequence acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated if necessary, and

sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

#### Influenza Virus Structure and Propagation

[0074] Influenza A viruses possess a genome of eight single-stranded negative-sense viral RNAs (vRNAs) that encode at least ten proteins. The influenza virus life cycle begins with binding of the hemagglutinin (HA) to sialic acid-containing receptors on the surface of the host cell, followed by receptor-mediated endocytosis. The low pH in late endosomes triggers a conformational shift in the HA, thereby exposing the N-terminus of the HA2 subunit (the so-called fusion peptide). The fusion peptide initiates the fusion of the viral and endosomal membrane, and the matrix protein (M1) and RNP complexes are released into the cytoplasm. RNPs consist of the nucleoprotein (NP), which encapsidates vRNA, and the viral polymerase complex, which is formed by the PA, PB1, and PB2 proteins. RNPs are transported into the nucleus, where transcription and replication take place. The RNA polymerase complex catalyzes three different reactions: synthesis of an mRNA with a 5' cap and 3' polyA structure, of a full-length complementary RNA (cRNA), and of genomic vRNA using the cRNA as a template. Newly synthesized vRNAs, NP, and polymerase proteins are then assembled into RNPs, exported from the nucleus, and transported to the plasma membrane, where budding of progeny virus particles occurs. The neuraminidase (NA) protein plays a crucial role late in infection by removing sialic acid from sialyloligosaccharides, thus releasing newly assembled virions from the cell surface and preventing the self aggregation of virus particles. Although virus assembly involves protein-protein and protein-vRNA interactions, the nature of these interactions is largely unknown.

[0075] Although influenza B and C viruses are structurally and functionally similar to influenza A virus, there are some differences. For example, influenza B virus does not have a M2 protein with ion channel activity but has BM2 and has a viral segment with both NA and NB sequences.

Influenza C virus has only seven viral segments.

#### Cells that can be Used to Produce Virus

[0076] Any cell, e.g., any avian or mammalian cell, such as avian eggs, a human, e.g., 293T or PER.C6® cells, or canine, bovine, equine, feline, swine, ovine, rodent, for instance mink, e.g., MvLu1 cells, or hamster, e.g., CHO cells, or non-human primate, e.g., Vero cells, including mutant cells, which supports efficient replication of influenza virus can be employed to isolate and/or propagate influenza viruses. Isolated viruses can be used to prepare a reassortant virus. In one embodiment, host cells for vaccine production are continuous mammalian or avian cell lines or cell strains. A complete characterization of the cells to be used, may be conducted so that appropriate tests for purity of the final product can be included. Data that can be used for the characterization of a cell includes (a) information on its origin, derivation, and passage history; (b) information on its growth and morphological characteristics; (c) results of tests of adventitious agents; (d) distinguishing features, such as biochemical, immunological, and cytogenetic patterns which allow the cells to be clearly recognized among other cell lines; and (e) results of tests for tumorigenicity. In one embodiment, the passage level, or population doubling, of the host cell used is as low as possible.

[0077] In one embodiment, the cells are WHO certified, or certifiable, continuous cell lines. The requirements for certifying such cell lines include characterization with respect to at least one of genealogy, growth characteristics, immunological markers, virus susceptibility tumorigenicity and storage conditions, as well as by testing in animals, eggs, and cell culture. Such characterization is used to confirm that the cells are free from detectable adventitious agents. In some countries, karyology may also be required. In addition, tumorigenicity may be tested in cells that are at the same passage level as those used for vaccine production. The virus may be purified by a process that has been shown to give consistent results, before vaccine production (see, e.g., World Health Organization, 1982).

[0078] Virus produced by the host cell may be highly purified prior to vaccine or gene therapy formulation. Generally, the purification procedures result in extensive removal of cellular DNA and other cellular components, and adventitious agents. Procedures that extensively degrade or denature DNA may also be used.

#### Influenza Vaccines

[0079] A vaccine includes an isolated recombinant influenza virus of the invention, and optionally one or more other isolated viruses including other isolated influenza viruses, one or more immunogenic proteins or glycoproteins of one or more isolated influenza viruses or one or more other pathogens, e.g., an immunogenic protein from one or more bacteria, non-influenza viruses, yeast or fungi, or isolated nucleic acid encoding one or more viral proteins (e.g., DNA vaccines) including one or more immunogenic proteins of the isolated influenza virus of the invention. In one embodiment, the influenza viruses of the invention may be vaccine vectors for influenza virus or other pathogens.

[0080] A complete virion vaccine may be concentrated by ultrafiltration and then purified by zonal centrifugation or by chromatography. Viruses other than the virus of the invention, such as those included in a multivalent vaccine, may be inactivated before or after purification using formalin or beta-propiolactone, for instance.

[0081] A subunit vaccine comprises purified glycoproteins. Such a vaccine may be prepared as follows: using viral suspensions fragmented by treatment with detergent, the surface antigens are purified, by ultracentrifugation for example. The subunit vaccines thus contain mainly HA protein, and also NA. The detergent used may be cationic detergent for example, such as hexadecyl trimethyl ammonium bromide (Bachmeyer, 1975), an anionic detergent such as ammonium deoxycholate (Laver & Webster, 1976); or a nonionic detergent such as that commercialized under the name TRITON X100. The hemagglutinin may also be isolated after treatment of the virions with a protease such as bromelain, and then purified. The subunit vaccine may be combined with an attenuated virus of the invention in a multivalent vaccine.

[0082] A split vaccine comprises virions which have been subjected to treatment with agents that dissolve lipids. A split vaccine can be prepared as follows: an aqueous suspension of the purified virus obtained as above, inactivated or not, is treated, under stirring, by lipid solvents such as ethyl ether or chloroform, associated with detergents. The dissolution of the viral envelope lipids results in fragmentation of the viral particles. The aqueous phase is recuperated containing the split vaccine, constituted mainly of hemagglutinin and neuraminidase with their original lipid environment removed, and the core or its degradation products. Then the residual infectious particles are inactivated if this has not already been done. The split vaccine may be combined with an attenuated virus of the invention in a multivalent vaccine.

[0083] Inactivated Vaccines. Inactivated influenza virus vaccines are provided by inactivating replicated virus using known methods, such as, but not limited to, formalin or  $\beta$ -propiolactone treatment. Inactivated vaccine types that can be used in the invention can include whole-virus (WV) vaccines or subvirion (SV) (split) vaccines. The WV vaccine contains intact, inactivated virus, while the SV vaccine contains purified virus disrupted with detergents that solubilize the lipid-containing viral envelope, followed by chemical inactivation of residual virus.

[0084] In addition, vaccines that can be used include those containing the isolated HA and NA surface proteins, which are referred to as surface antigen or subunit vaccines.

[0085] Live Attenuated Virus Vaccines. Live, attenuated influenza virus vaccines, such as those including a recombinant virus of the invention can be used for preventing or treating influenza virus infection. Attenuation may be achieved in a single step by transfer of attenuated genes from an attenuated donor virus to a replicated isolate or reassorted virus according to known methods. Since resistance to influenza A virus is mediated primarily by the development of an immune response to the HA and/or NA glycoproteins, the genes coding for these surface antigens come from the reassorted viruses or clinical isolates. The attenuated genes are derived from an attenuated

parent. In this approach, genes that confer attenuation generally do not code for the HA and NA glycoproteins.

[0086] Viruses (donor influenza viruses) are available that are capable of reproducibly attenuating influenza viruses, e.g., a cold adapted (ca) donor virus can be used for attenuated vaccine production. Live, attenuated reassortant virus vaccines can be generated by mating the ca donor virus with a virulent replicated virus. Reassortant progeny are then selected at 25° C. (restrictive for replication of virulent virus), in the presence of an appropriate antiserum, which inhibits replication of the viruses bearing the surface antigens of the attenuated ca donor virus. Useful reassortants are: (a) infectious, (b) attenuated for seronegative non-adult mammals and immunologically primed adult mammals, (c) immunogenic and (d) genetically stable. The immunogenicity of the ca reassortants parallels their level of replication. Thus, the acquisition of the six transferable genes of the ca donor virus by new wild-type viruses has reproducibly attenuated these viruses for use in vaccinating susceptible mammals both adults and non-adult.

[0087] Other attenuating mutations can be introduced into influenza virus genes by site-directed mutagenesis to rescue infectious viruses bearing these mutant genes. Attenuating mutations can be introduced into non-coding regions of the genome, as well as into coding regions. Such attenuating mutations can also be introduced into genes other than the HA or NA, e.g., the PB2 polymerase gene. Thus, new donor viruses can also be generated bearing attenuating mutations introduced by site-directed mutagenesis, and such new donor viruses can be used in the production of live attenuated reassortants vaccine candidates in a manner analogous to that described above for the ca donor virus. Similarly, other known and suitable attenuated donor strains can be reassorted with influenza virus to obtain attenuated vaccines suitable for use in the vaccination of mammals.

[0088] In one embodiment, such attenuated viruses maintain the genes from the virus that encode antigenic determinants substantially similar to those of the original clinical isolates. This is because the purpose of the attenuated vaccine is to provide substantially the same antigenicity as the original clinical isolate of the virus, while at the same time lacking pathogenicity to the degree that the vaccine causes minimal chance of inducing a serious disease condition in the vaccinated mammal.

[0089] The viruses in a multivalent vaccine can thus be attenuated or inactivated, formulated and administered, according to known methods, as a vaccine to induce an immune response in an animal, e.g., a mammal. Methods are well-known in the art for determining whether such attenuated or inactivated vaccines have maintained similar antigenicity to that of the clinical isolate or high growth strain derived therefrom. Such known methods include the use of antisera or antibodies to eliminate viruses expressing antigenic determinants of the donor virus; chemical selection (e.g., amantadine or rimantadine); HA and NA activity and inhibition; and nucleic acid screening (such as probe hybridization or PCR) to confirm that donor genes encoding the antigenic determinants (e.g., HA or NA genes) are not present in the attenuated viruses.

#### Pharmaceutical Compositions

[0090] Pharmaceutical compositions of the present invention, suitable for inoculation, e.g., nasal, parenteral or oral administration, comprise one or more influenza virus isolates, e.g., one or more attenuated or inactivated influenza viruses, a subunit thereof, isolated protein(s) thereof, and/or isolated nucleic acid encoding one or more proteins thereof, optionally further comprising sterile aqueous or non-aqueous solutions, suspensions, and emulsions. The compositions can further comprise auxiliary agents or excipients, as known in the art. The composition of the invention is generally presented in the form of individual doses (unit doses).

[0091] Conventional vaccines generally contain about 0.1 to 200 µg, e.g., 30 to 100 µg, 0.1 to 2 µg, 0.5 to 5 µg, 1 to 10 µg, 10 µg to 20 µg, 15 µg to 30 µg, or 10 to 30 µg, of HA from each of the strains entering into their composition. The vaccine forming the main constituent of the vaccine composition of the invention may comprise a single influenza virus, or a combination of influenza viruses, for example, at least two or three influenza viruses, including one or more reassortant(s).



[0092] Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and/or emulsions, which may contain auxiliary agents or excipients known in the art. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Carriers or occlusive dressings can be used to increase skin permeability and enhance antigen absorption. Liquid dosage forms for oral administration may generally comprise a liposome solution containing the liquid dosage form. Suitable forms for suspending liposomes include emulsions, suspensions, solutions, syrups, and elixirs containing inert diluents commonly used in the art, such as purified water. Besides the inert diluents, such compositions can also include adjuvants, wetting agents, emulsifying and suspending agents, or sweetening, flavoring, or perfuming agents.

[0093] When a composition of the present invention is used for administration to an individual, it can further comprise salts, buffers, adjuvants, or other substances which are desirable for improving the efficacy of the composition. For vaccines, adjuvants, substances which can augment a specific immune response, can be used. Normally, the adjuvant and the composition are mixed prior to presentation to the immune system, or presented separately, but into the same site of the organism being immunized.

[0094] Heterogeneity in a vaccine may be provided by mixing replicated influenza viruses for at least two influenza virus strains, such as 2-20 strains or any range or value therein. Vaccines can be provided for variations in a single strain of an influenza virus, using techniques known in the art.

[0095] A pharmaceutical composition according to the present invention may further or additionally comprise at least one chemotherapeutic compound, for example, for gene therapy, immunosuppressants, anti-inflammatory agents or immune enhancers, and for vaccines, chemotherapeutics including, but not limited to, gamma globulin, amantadine, guanidine, hydroxybenzimidazole, interferon- $\alpha$ , interferon- $\beta$ , interferon- $\gamma$ , tumor necrosis factor- $\alpha$ , thiosemicarbazones, methisazone, rifampin, ribavirin, a pyrimidine analog, a purine analog, foscarnet, phosphonoacetic acid, acyclovir, dideoxynucleosides, a protease inhibitor, or ganciclovir.

[0096] The composition can also contain variable but small quantities of endotoxin-free formaldehyde, and preservatives, which have been found safe and not contributing to undesirable effects in the organism to which the composition is administered.

#### Pharmaceutical Purposes

[0097] The administration of the composition (or the antisera that it elicits) may be for either a "prophylactic" or "therapeutic" purpose. When provided prophylactically, the compositions of the invention which are vaccines are provided before any symptom or clinical sign of a pathogen infection becomes manifest. The prophylactic administration of the composition serves to prevent or attenuate any subsequent infection. When provided prophylactically, the gene therapy compositions of the invention, are provided before any symptom or clinical sign of a disease becomes manifest. The prophylactic administration of the composition serves to prevent or attenuate one or more symptoms or clinical signs associated with the disease.

[0098] When provided therapeutically, a viral vaccine is provided upon the detection of a symptom or clinical sign of actual infection. The therapeutic administration of the compound(s) serves to attenuate any actual infection. When provided therapeutically, a gene therapy composition is provided upon the detection of a symptom or clinical sign of the disease. The therapeutic administration of the compound(s) serves to attenuate a symptom or clinical sign of that disease.

[0099] Thus, a vaccine composition of the present invention may be provided either before the onset of infection (so as to prevent or attenuate an anticipated infection) or after the initiation of an actual infection. Similarly, for gene therapy, the composition may be provided before any symptom or clinical sign of a disorder or disease is manifested or after one or more symptoms are detected.

[0100] A composition is said to be "pharmacologically acceptable" if its administration can be tolerated by a recipient mammal. Such an agent is said to be administered in a "therapeutically effective amount" if the amount administered is physiologically significant. A composition of the

present invention is physiologically significant if its presence results in a detectable change in the physiology of a recipient patient, e.g., enhances at least one primary or secondary humoral or cellular immune response against at least one strain of an infectious influenza virus.

[0101] The “protection” provided need not be absolute, i.e., the influenza infection need not be totally prevented or eradicated, if there is a statistically significant improvement compared with a control population or set of mammals. Protection may be limited to mitigating the severity or rapidity of onset of symptoms or clinical signs of the influenza virus infection.

#### Pharmaceutical Administration

[0102] A composition of the present invention may confer resistance to one or more pathogens, e.g., one or more influenza virus strains, by either passive immunization or active immunization. In active immunization, an attenuated live vaccine composition is administered prophylactically to a host (e.g., a mammal), and the host's immune response to the administration protects against infection and/or disease. For passive immunization, the elicited antisera can be recovered and administered to a recipient suspected of having an infection caused by at least one influenza virus strain. A gene therapy composition of the present invention may yield prophylactic or therapeutic levels of the desired gene product by active immunization.

[0103] In one embodiment, the vaccine is provided to a mammalian female (at or prior to pregnancy or parturition), under conditions of time and amount sufficient to cause the production of an immune response which serves to protect both the female and the fetus or newborn (via passive incorporation of the antibodies across the placenta or in the mother's milk).

[0104] The present invention thus includes methods for preventing or attenuating a disorder or disease, e.g., an infection by at least one strain of pathogen. As used herein, a vaccine is said to prevent or attenuate a disease if its administration results either in the total or partial attenuation (i.e., suppression) of a clinical sign or condition of the disease, or in the total or partial immunity of the individual to the disease. As used herein, a gene therapy composition is said to prevent or attenuate a disease if its administration results either in the total or partial attenuation (i.e., suppression) of a clinical sign or condition of the disease, or in the total or partial immunity of the individual to the disease.

[0105] A composition having at least one influenza virus of the present invention, including one which is attenuated and one or more other isolated viruses, one or more isolated viral proteins thereof, one or more isolated nucleic acid molecules encoding one or more viral proteins thereof, or a combination thereof, may be administered by any means that achieve the intended purposes.

[0106] For example, administration of such a composition may be by various parenteral routes such as subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intranasal, oral or transdermal routes. Parenteral administration can be accomplished by bolus injection or by gradual perfusion over time.

[0107] A typical regimen for preventing, suppressing, or treating an influenza virus related pathology, comprises administration of an effective amount of a vaccine composition as described herein, administered as a single treatment, or repeated as enhancing or booster dosages, over a period up to and including between one week and about 24 months, or any range or value therein.

[0108] According to the present invention, an “effective amount” of a composition is one that is sufficient to achieve a desired effect. It is understood that the effective dosage may be dependent upon the species, age, sex, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect wanted. The ranges of effective doses provided below are not intended to limit the invention and represent dose ranges.

[0109] The dosage of a live, attenuated or killed virus vaccine for an animal such as a mammalian adult organism may be from about  $10^{2.2}$ - $10^{2.0}$ , e.g.,  $10^{3.3}$ - $10^{1.2}$ ,  $10^{2.2}$ - $10^{1.0}$ ,  $10^{5.5}$ - $10^{1.1}$ ,  $10^{6.6}$ - $10^{1.5}$ ,  $10^{2.2}$ - $10^{1.0}$ , or  $10^{1.5}$ - $10^{2.0}$  plaque forming units (PFU)/kg, or any range or value therein. The dose of one viral isolate vaccine, e.g., in an inactivated vaccine, may range from about 0.1 to 1000, e.g., 0.1 to 10 g, 1 to 20 g, 30 to

100 g, 10 to 50 g, 50 to 200 g, or 150 to 300 g, of HA protein. However, the dosage should be a safe and effective amount as determined by conventional methods, using existing vaccines as a starting point.

[0110] The dosage of immunoreactive HA in each dose of replicated virus vaccine may be standardized to contain a suitable amount, e.g., 0.1 µg to 1 µg, 0.5 µg to 5 µg, 1 µg to 10 µg, 10 µg to 20 µg, 15 µg to 30 µg, or 30 µg to 100 µg or any range or value therein, or the amount recommended by government agencies or recognized professional organizations. The quantity of NA can also be standardized, however, this glycoprotein may be labile during purification and storage.

[0111] The dosage of immunoreactive HA in each dose of replicated virus vaccine can be standardized to contain a suitable amount, e.g., 1-50 µg or any range or value therein, or the amount recommended by the U.S. Public Health Service (PHS), which is usually 15 µg, per component for older children >3 years of age, and 7.5 g per component for children <3 years of age. The quantity of NA can also be standardized, however, this glycoprotein can be labile during the processor purification and storage (Kendal et al., 1980; Kerr et al., 1975). Each 0.5-ml dose of vaccine may contain approximately 0.1 to 0.5 billion viral particles, 0.5 to 2 billion viral particles, 1 to 50 billion virus particles, 1 to 10 billion viral particles, 20 to 40 billion viral particles, 1 to 5 billion viral particles, or 40 to 80 billion viral particles.

#### Exemplary Viruses

[0112] Useful modifications of influenza neuraminidase (NA) proteins are described herein that stabilize hemagglutinin (HA) protein during egg-passages of influenza viruses that express those modified neuraminidase proteins. Modified nucleic acids are also described that encode such modified neuraminidase proteins. The modifications can include deletions, substitutions and combinations thereof within the neuraminidase protein and nucleic acid sequences. Viruses that express such modified neuraminidase proteins exhibit significantly reduced acquisition of antigenicity-compromising mutations in hemagglutinin (HA) during growth of influenza in eggs.

[0113] For example, in some cases the modified neuraminidase can have at least one, or at least two, or at least three modifications. Amino acid positions within influenza neuraminidase proteins that can be modified include, for example, one or more amino acids within positions 29-35, one or more amino acids within positions 44-52, one or more amino acids within positions 144-154, one or more amino acid positions within 240-250, one or more amino acids within positions 326-333, one or more amino acid positions within 344-350, one or more amino acid positions within 365-375, and combinations thereof, based on N2 numbering. For example, the amino acid(s) can be any amino acid within these positions such as any of the amino acids listed in the table below.

TABLE-US-00001 Original Exemplary Alternative Residue Substitutions

Substitutions	Ala (A)
val; leu; ile	Val Arg (R) lys; gln; asn Lys Asn (N) gln; his; lys; arg Gln Asp (D) Glu, Asn Glu; Asn Cys (C) Ser Ser Gln (Q) Asn Asn Glu (E) Asp Asp Gly (G) Pro Pro His (H) asn; gln; lys; arg; gln; Arg; Gln Ile (I) leu; val; met; ala; phe Leu norleucine Leu (L) norleucine; ile; val; met; Ile ala; phe Lys (K) arg; gln; asn Arg Met (M) leu; phe; ile Leu Phe (F) leu; val; ile; ala Leu Pro (P) Gly Gly Ser (S) Thr Thr Thr (T) Ser, Ala Ser, Als Trp (W) Tyr Tyr Tyr (Y) trp; phe; thr; ser Phe Val (V) ile; leu; met; phe; ala; Leu norleucine

In some cases, a selected amino acid within positions 29-35, positions 44-52, positions 144-154, positions 326-333, positions within 344-350, positions within 365-375, can have a conservative substitution. However, in other cases, the selected amino acid within positions 29-35, positions 44-52, positions 144-150, positions 326-333, positions within 344-350, positions within 365-375, can have a non-conservative substitution.

[0114] For example, a modified neuraminidase can have a deletion of at least one proline, asparagine, glutamine, valine, or a combination of a proline, one or more asparagine(s), a glutamine, and a valine within positions 44-52 of the modified neuraminidase. A modified neuraminidase can have a substitution (replacement) of a threonine within positions 29-35, where

the replacement is any amino acid. A modified neuraminidase can have a substitution (replacement) of a threonine or an aspartic acid within positions 145-154 or 365 to 375, where the replacement is any amino acid. A modified neuraminidase can have a substitution (replacement) of an asparagine within positions 326-333, where the replacement is any amino acid. A modified neuraminidase can have a substitution (replacement) of a histidine within positions 345-350, where the replacement is any amino acid. Exemplary substitutions (replacements) for various types of amino acids are provided in the table above.

[0115] One example of an influenza A virus (A/Yokohama/2013/2003(H3N2)) neuraminidase protein sequence is provided below

TABLE-US-00002 (SEQ ID NO: 55) 1 MNPNQKIITI GSVSLTISTI  
 CFFMQIAILI **TT**VTLHFKQY 41 EFNSP**PNNQV** MLCEPTIHER NITEIVYLTN  
 TTIEKEICPK 81 LAEYRNWSKP QCNITGFAPF SKDNSIRLSA GGDIWVTREP 121  
 YVSCDPDKCY QFALGQGTTL NNVHSN**D**IVH DRTPYRTLML 161 NELGVPFHLG  
 TKQVCIAWSS SSCHDGKAWL HVCVTGDDEN 201 ATASFIYNGR LADSIWSWSK  
 KILRTQESEC VCINGTCTVV 241 MTDGSASGKA DTKILFIEEG KIVHTSTLSG  
 SAQHVEECSC 281 YPRYPGVRCV CRDNWKGSNR PIVDINIKDY SIVSSYVCSG 321  
 LVGDTPRK**ND** SSSSSHCLDP NNEEGG**H**GVK GWAFFDDGNDV 361 WMGRTISEKL  
 RSGYETFKVI EGWSNPNSKL QINRQVIVDR 401 GNRSGYSGIF SVEGKSCINR  
 CFYVELIRGR KQETEVLWTS 441 NSIVVFCGTS GTYGTGSWPD GADINLMPI

Amino acids that can be modified to improve the stability of co-expressed HA are highlighted in bold and with underlining within the sequence shown above. A nucleic acid that encodes such an influenza A virus (A/Yokohama/2013/2003(H3N2)) neuraminidase protein sequence is shown below

TABLE-US-00003 (SEQ ID NO: 56) 1 AGCAAAAGCA GGAGTAAAGA  
 TGAATCCAAA TCAAAAGATA 41 ATAACGATTG GCTCTGTTTC CCTCACCATT  
 TCCACAATAT 81 GCTTCTTCAT GCAAATTGCC ATCCTGATAA CTACTGTAAC 121  
 ATTGCATTTC AAGCAATATG AATTCAACTC CCCCCCAAAC 161 AACCAAGTGA  
 TGCTGTGTGA ACCAACAATA ATAGAAAGAA 201 ACATAACAGA GATAGTGTAT  
 CTGACCAACA CCACCATAGA 241 GAAGGAAATA TGCCCCAAAC  
 TAGCAGAATA CAGAAATTGG 281 TCAAAGCCGC AATGTAACAT TACAGGATTT  
 GCACCTTTTT 321 CTAAGGACAA TTCGATTCCG CTTTCCGCTG GTGGGGACAT  
 361 CTGGGTGACA AGAGAACCTT ATGTGTCATG CGATCCTGAC 401  
 AAGTGTTATC AATTTGCCCT TGGACAGGGA ACAACACTAA 441 ACAACGTGCA  
 TTCAAATGAC ATAGTACATG ATAGGACCCC 461 TTATCGGACC CTATTGATGA  
 ATGAGTTGGG TGTTCCATTT 521 CATCTGGGGA CCAAGCAAGT GTGCATAGCA  
 TGGTCCAGCT 561 CAAGTTGTCA CGATGGAAAA GCATGGCTGC ATGTTTGTGT  
 601 AACGGGGGAT GATGAAAATG CAACTGCTAG CTTCAATTAC 641  
 AATGGGAGGC TTGCAGATAG TATTGTTTCA TGGTCCAAAA 681 AAATCCTCAG  
 GACCCAGGAG TCAGAATGCG TTTGTATCAA 721 TGaAACTTGT ACAGTAGTAA  
 TGACTGATGG GAGTGCTTCA 761 GGAAAAGCTG ATACTAAAAT ACTATTCATT  
 GAGGAGGGGA 801 AAATTGTTCA TACTAGCACA TTATCAGGAA GTGCTCAGCA  
 841 TGTCGAGGAG TGCTCCTGTT ATCCTCGATA TCCTGGTGTC 881  
 AGATGTGTCT GCAGAGACAA CTGGAAAGGC TCCAATAGGC 921  
 CCATCGTAGA TATAAACATA AAGGATTATA GGATTGTTTC 961 GAGTTATGTG  
 TGCTCAGGAC TTGTTGGAGA GACACCCAGA 1001 AAAAACGACA  
 GCTCCAGCAG TAGCCATTGC TTGGATCCAA 1041 ACAATGAGGA  
 AGGTGGTCAT GGAGTGAAAG GCTGGGCCTT 1081 TGATGATGGA  
 AATGACGTGT GGATGGGAAG AACGATCAGC 1121 GAGAAGTTAC  
 GCTCAGGATA TGAAACCTTC AAAGTCATTG 1161 AAGGCTGGTC  
 CAACCCTAAC TCGAAATTGC AGATAAATAG 1201 GCAAGTCATA

GTTGACAGAG GATAACAGGTC CGGTATTCT 1241 GGTATTTTCT CTGTTGAAGG  
 GAAAAGCTGC ATCAATCGGT 1281 GCTTTTATGT GGAGTTGATA  
 AGGGGAAGAA AACAGGAAAC 1321 TGAAGTCTTG TGGACCTCAA  
 ACAGTATTGT TGTGTTTTGT 1361 GGCACCTCAG GTACATATGG AACAGGCTCA  
 TGGCCTGATG 1401 GGGCGGACAT GAATCTCATG CCTATATAAG CTTTCGGAAT  
 1441 TTTAGAAAAA AACTCCTTGT TTCTACT

Modifications at the specified positions in neuraminidase can confer enhanced growth of the virus.  
 [0116] Another example of an influenza A virus (A/Yokohama/47/2002(H1N2))) neuraminidase sequence is shown below, with positions of modifications highlighted in bold and with underlining.

TABLE-US-00004 (SEQ ID NO: 57)

			10	
20	30	40	MNPNQKIITI	GSVSLTIATI
CFLMQIAILV	<u>TT</u> VTLHFKQY	50		
60	70	80	ECNSP <b><u>PNNQV</u></b>	MLCEPTIER
NITEIVYLTN	TTIEKEICPK	90		100
110	120	130	140	150
	LAEYRNWSKP	QCNITGFAPF	SKDNSIRLSA	GGDIWVTREP
170	180	190		200
	QFALGQGTTL	NNGHSN <b><u>D</u></b> TVH	DRTPYRTL	LLM
220	230	240	250	260
	SSCHDGKAWL	HVCVTGDDGN		NELGVPFHLG
270	280	290	300	310
	VCINGTCTVV	240	ATASFIYNGR	LVDSIGSWSK
330	340	350		360
	CRDNWKGSNR	PIVDINVKDY	SIVSSYVCSG	
380	390	400	410	420
	NNEEGG <b><u>H</u></b> GVK	GWAFDDGNDV		LVGDTPRK <b><u>ND</u></b>
440	450	460		
	QINRQVIVDR	WMGRTISEKL	RSGYETFKVI	
480	490	500		
	NQETEVWLTS	GNRSGYSGIF	SVEGKSCINR	
520	530	540		
	GADINLMPI			

Amino acids that can be modified to improve the stability of co-expressed HA are highlighted in bold and with underlining within the sequence shown above.

[0117] In some cases, in one or more modifications can also be introduced into HA, PA, PB1, PB2, NP, M1, M2, NS2, PB1-F2, PA-X, and/or NS1 proteins (and nucleic acids encoding such proteins).

[0118] Enhanced growth of the virus when passaged through embryonated chicken eggs or cultured cells is observed when the modified NA proteins are expressed and such expression can result in significantly higher viral titers. Thus, the invention provides a method for making influenza viruses with enhanced replication in cell culture or in embryonated chicken eggs. The method includes providing cells suitable for influenza vaccine production; modifying nucleic acids encoding the neuraminidase; and isolating virus strains with enhanced growth relative to the one or more unmodified viral isolates. In some cases, a method for making influenza viruses with enhanced replication in cell culture can involve, serially culturing one or more influenza virus isolates in embryonated chicken eggs; and isolating serially cultured virus with enhanced growth relative to the one or more isolates prior to serial culture. In some cases, the viruses can be grown or passaged within cells in culture, e.g., MDCK or Vero cells.

[0119] The modified neuraminidases can be expressed in a variety of influenza strains. For example, A/Puerto Rico/8/34 (H1N1), "PR8," virus often serves as the genetic backbone for generation of inactivated influenza vaccines. Some vaccine strains based on PR8 backbone can replicate to relatively low titers in eggs and cell culture, resulting in delayed vaccine production

and vaccine shortage. However, expression of the modified neuraminidases described herein can improve replication of the PR8 (and other) influenza strains.

[0120] In one embodiment of the invention, vectors for vRNA production can include a vector comprising a promoter operably linked to a modified NA DNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus PB1 DNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus PB2 DNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus HA DNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus NP DNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus NA DNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus M DNA linked to a transcription termination sequence, and a vector comprising a promoter operably linked to an influenza virus NS DNA linked to a transcription termination sequence. In one embodiment, the DNAs for vRNA production of PB1, PB2, PA, NP, M, and NS, have sequences from an influenza virus that replicates to high titers in cultured mammalian cells such as MDCK cells, Vero cells or PER.C6® cells or embryonated eggs, and/or from a vaccine virus, e.g., one that does not cause significant disease in humans. The DNA for vRNA production of NA may be from any NA, e.g., any of N1-N11, and the DNA for vRNA production of HA may be from any HA, e.g., H1-H18. In one embodiment, the DNAs for vRNA production may be for an influenza B or C virus. The DNAs for vRNA production of NA and HA may be from different strains or isolates (6:1:1 reassortants) or from the same strain or isolate (6:2 reassortants), or the NA may be from the same strain or isolate as that for the internal genes (7:1 reassortant). Vectors for mRNA production can include a vector encoding a modified NA, a vector encoding influenza virus PA, a vector encoding influenza virus PB1, a vector encoding influenza virus PB2, and a vector encoding influenza virus NP, and optionally one or more vectors encoding NP, NS, M, e.g., M1 and M2, HA or NA. The vectors encoding viral proteins may further include a transcription termination sequence.

[0121] Other reassortants with internal genes from other PR8 isolates or vaccine viruses may be employed in recombinant reassortant viruses of the invention. In particular, 5:1:2 reassortants having UW-PR8 PB1, PB2, PA, NP, and M (“5”) and PR8(Cam) NS (“1”); 6:1:1 reassortants having UW-PR8 (modified) NA, PB1, PB2, PA, NP, and M (“6”) and PR8(Cam) NS (“1”); and 7:1 reassortants having UW-PR8 PB1, PB2, PA, NP, M, (modified) NA, and NS (“7”) may be employed.

[0122] The neuraminidases that can be modified can have sequences that vary from those described herein. However, in some cases, the modified neuraminidases can have substantially the same activity as a corresponding polypeptide described by sequence herein. As used herein, “substantially the same activity” includes an activity that is about 0.1%, 1%, 10%, 30%, 50%, 90%, e.g., up to 100% or more activity, or a detectable protein level that is about 80%, 90% or more protein level, of the corresponding protein described herein. In one embodiment, the nucleic acid encodes a polypeptide which is substantially the same as, e.g., having at least 80%, e.g., 90%, 92%, 95%, 97%, 98%, or 99%, including any integer between 80 and 99, contiguous amino acid sequence identity to a polypeptide encoded by one of sequences described herein. In one embodiment, the isolated and/or purified nucleic acid molecule comprises a nucleotide sequence which is substantially the same as, e.g., having at least 50%, e.g., 60%, 70%, 80% or 90%, including any integer between 50 and 100, or more contiguous nucleic acid sequence identity to one of the nucleic acid sequences described herein. In one embodiment, a nucleic acid also encodes a polypeptide having at least 80%, e.g., 90%, 92%, 95%, 97%, 98%, or 99%, including any integer between 80 and 99, contiguous amino acid sequence identity to a polypeptide described herein.

[0123] In one embodiment, a modified influenza virus neuraminidase polypeptide has one or more, for instance, 2, 5, 10, 15, 20 or more, conservative amino acids substitutions, e.g., conservative

substitutions of up to 10% or 20% of 2, 5, 10, 15, 20 or more, of a combination of conservative and non-conservative amino acids substitutions, e.g., conservative substitutions of up to 10% or 20% of the residues, or relative to a polypeptide with one of the sequences disclosed herein.

[0124] The invention thus includes the use of isolated and purified vectors or plasmids, which express or encode influenza virus proteins, or express or encode influenza vRNA, both native and recombinant vRNA. The vectors comprise influenza cDNA, e.g., influenza A (e.g., any influenza A gene including any of the 18 HA or 11 NA subtypes), B or C DNA (see Fields *Virology* (Fields et al. (eds.), Lippincott, Williams and Wilkins (2006), which is specifically incorporated by reference herein). Any suitable promoter or transcription termination sequence may be employed to express a protein or peptide, e.g., a viral protein or peptide, a protein or peptide of a nonviral pathogen, or a therapeutic protein or peptide.

[0125] A composition or plurality of vectors of the invention may also comprise a heterologous gene or open reading frame of interest, e.g., a foreign gene encoding an immunogenic peptide or protein useful as a vaccine or in gene replacement, for instance, may encode an epitope useful in a cancer therapy or vaccine, or a peptide or polypeptide useful in gene therapy. When preparing virus, the vector or plasmid comprising the gene or cDNA of interest may substitute for a vector or plasmid for an influenza viral gene or may be in addition to vectors or plasmids for all influenza viral genes. Thus, another embodiment of the invention comprises a composition or plurality of vectors as described above in which one of the vectors is replaced with, or further comprises, 5' influenza virus sequences optionally including 5' influenza virus coding sequences or a portion thereof, linked to a desired nucleic acid sequence, e.g., a desired cDNA, linked to 3' influenza virus sequences optionally including 3' influenza virus coding sequences or a portion thereof. In one embodiment, the desired nucleic acid sequence such as a cDNA is in an antisense (antigenomic) orientation. The introduction of such a vector in conjunction with the other vectors described above to a host cell permissive for influenza virus replication results in recombinant virus comprising vRNA corresponding to the heterologous sequences of the vector.

[0126] The promoter in a vector for vRNA production may be a RNA polymerase I promoter, a RNA polymerase II promoter, a RNA polymerase III promoter, a T7 promoter, or a T3 promoter, and optionally the vector comprises a transcription termination sequence such as a RNA polymerase I transcription termination sequence, a RNA polymerase II transcription termination sequence, a RNA polymerase III transcription termination sequence, or a ribozyme. Ribozymes within the scope of the invention include, but are not limited to, tetrahymena ribozymes, RNase P, hammerhead ribozymes, hairpin ribozymes, hepatitis ribozyme, as well as synthetic ribozymes. In one embodiment, the RNA polymerase I promoter is a human RNA polymerase I promoter.

[0127] The promoter or transcription termination sequence in a vRNA or virus protein expression vector may be the same or different relative to the promoter or any other vector. In one embodiment, the vector or plasmid which expresses influenza vRNA comprises a promoter suitable for expression in at least one particular host cell, e.g., avian or mammalian host cells such as canine, feline, equine, bovine, ovine, or primate cells including human cells, or for expression in more than one host.

[0128] In one embodiment, at least one vector for vRNA comprises a RNA polymerase II promoter linked to a ribozyme sequence linked to viral coding sequences linked to another ribozyme sequences, optionally linked to a RNA polymerase II transcription termination sequence. In one embodiment, at least 2, e.g., 3, 4, 5, 6, 7 or 8, vectors for vRNA production comprise a RNA polymerase II promoter, a first ribozyme sequence, which is 5' to a sequence corresponding to viral sequences including viral coding sequences, which is 5' to a second ribozyme sequence, which is 5' to a transcription termination sequence. Each RNA polymerase II promoter in each vRNA vector may be the same or different as the RNA polymerase II promoter in any other vRNA vector. Similarly, each ribozyme sequence in each vRNA vector may be the same or different as the ribozyme sequences in any other vRNA vector. In one embodiment, the ribozyme sequences in a

single vector are not the same.

[0129] In one embodiment, the invention provides a plurality of influenza virus vectors for a reassortant, comprising a vector for vRNA production comprising a promoter operably linked to a modified influenza virus NA DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus PA DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus PB1 DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus PB2 DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus HA DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus NP DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus NA DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus M DNA linked to a transcription termination sequence, and a vector for vRNA production comprising a promoter operably linked to an influenza virus NS cDNA linked to a transcription termination sequence, wherein the DNAs for the modified NA, PB1, PB2, PA, NP, NS, and M are from one or more influenza vaccine seed viruses and contain two or more of the characteristic residues at the specified position(s); and a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus NA, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus PA, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus PB1, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus PB2, and a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus NP, and optionally a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus HA, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus NA, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus M1, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus M2, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus NS1, or a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus NS2. In one embodiment, at least one vector comprises sequences corresponding to those encoding PB1, PB2, PA, NP, M, or NS, or a portion thereof, having substantially the same activity as a corresponding polypeptide described herein or encoded by a nucleic acid described herein. Optionally, two vectors may be employed in place of the vector comprising a promoter operably linked to an influenza virus M cDNA linked to a transcription termination sequence, e.g., a vector comprising a promoter operably linked to an influenza virus M1 cDNA linked to a transcription termination sequence and a vector comprising a promoter operably linked to an influenza virus M2 cDNA linked to a transcription termination sequence.

[0130] A plurality of the vectors of the invention may be physically linked or each vector may be present on an individual plasmid or other, e.g., linear, nucleic acid delivery vehicle. In one embodiment, each vRNA production vector is on a separate plasmid. In one embodiment, each mRNA production vector is on a separate plasmid.

[0131] The invention also provides a method to prepare influenza virus. The method comprises contacting a cell with a plurality of the vectors of the invention, e.g., sequentially or simultaneously, in an amount effective to yield infectious influenza virus. The invention also includes isolating virus from a cell contacted with the plurality of vectors. Thus, the invention further provides isolated virus, as well as a host cell contacted with the plurality of vectors or virus of the invention. In another embodiment, the invention includes contacting the cell with one or



more vectors, either vRNA or protein production vectors, prior to other vectors, either vRNA or protein production vectors. In one embodiment, the promoter for vRNA vectors employed in the method is a RNA polymerase I promoter, a RNA polymerase II promoter, a RNA polymerase III promoter, a T3 promoter or a T7 promoter. In one embodiment, the RNA polymerase I promoter is a human RNA polymerase I promoter. In one embodiment, each vRNA vector employed in the method is on a separate plasmid. In one embodiment, the vRNA vectors employed in the method are on one plasmid or on two or three different plasmids. In one embodiment, each mRNA vector employed in the method is on a separate plasmid. In one embodiment, the mRNA vectors for PA, PB1, PB2 and NP employed in the method are on one plasmid or on two or three different plasmids.

#### EXEMPLARY EMBODIMENTS

[0132] An isolated recombinant influenza virus comprising a selected NA viral segment encoding a plurality of selected residues or a deletion of residues in NA is provided. In one embodiment, the selected NA viral segment does not encode a NA having a threonine at residue 32, does not encode a NA having an aspartic acid at position 147, does not encode a NA having a threonine at position 148, does not encode a NA having an aspartic acid at position 151, does not encode a NA having an asparagine at position 245, does not encode a NA having an asparagine at residue 329, does not encode a NA having a glycine at position 346, does not encode a NA having a histidine at residue 347, or encodes a NA having a deletion of one or more of residues 46 to 50, or any combination thereof, wherein the numbering is based on N2, wherein the recombinant influenza virus has enhanced replication in avian eggs or has a reduction in HA mutations when grown in avian eggs relative to a corresponding influenza virus that has a NA that encodes a threonine at residue 32, does not have a deletion of residues 46 to 50, encodes an aspartic acid at position 147, encodes a threonine at residue 148, encodes an aspartic acid at residue 151, encodes an asparagine at residue 245, encodes an asparagine at residue 329, encodes a histidine at residue 347, or any combination thereof. In one embodiment, the selected NA viral segment does not have an aspartic acid at position 147, does not have an asparagine at residue 329, and does not have an arginine or a histidine at residue 347. In one embodiment, the selected NA viral segment does not a threonine at position 148, does not have an aspartic acid at position 151, and does not have an asparagine at position 245. In one embodiment, the selected NA viral segment does not have an aspartic acid at position 147, does not have an asparagine at residue 329, and does not have an arginine or a histidine at residue 347. In one embodiment, the selected NA viral segment does not a threonine at position 148, does not have an aspartic acid at position 151, and does not have an asparagine at position 245. In one embodiment, the selected NA viral segment has at least two of: N or Q at position 147, D or E at residue 329, or Q or G at residue 347. In one embodiment, the selected NA viral segment has at least two of: K, R or H at position 148, E or Q at position 151, or S, I, T, V or G at position 245. In one embodiment, the selected NA viral segment has N or Q at position 147, D or E at residue 329, and Q or G at residue 347. In one embodiment, the selected NA viral segment has K, R or H at position 148, E or Q at position 151, and S, I, T, V or G at position 245. In one embodiment, the isolated recombinant influenza virus is a reassortant. In one embodiment, the NA viral segment encodes a NA that has at least 90% amino acid sequence identity to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50 or SEQ ID NO:54. In one embodiment, the NA viral segment encodes a NA that has at least 90% amino acid sequence identity to SEQ ID NO:2. In one embodiment, the NA viral segment encodes a N2, N3, N7, or N9. In one embodiment, the NA viral segment encodes a N1, N4, N5, N6, N8, N10 or N11. In one embodiment, the residue at position 32 is A, I, G, or L. In one embodiment, the deletion is a deletion of residues 46 to 50. In one embodiment, the residue at position 147 is N or Q. In one embodiment, the residue at position 148 is K, R or H. In one embodiment, the residue at position 151 is E, N or Q. In one embodiment, the residue at position 245 is S, T, I, L, A, N, W, Y, P, V, or G. In one embodiment, the residue at position 329 is D or E. In one embodiment, the residue at

position 346 is S, T, P, Y, W, A, N, I, L, or V. In one embodiment, the residue at position 347 is G, Q, S, T, Y, C or W. In one embodiment, the residue at position 147 is N or Q, the residue at position 329 is D or E, the residue at position 347 is G, Q, S, T, Y, C or W, or any combination thereof. In one embodiment, the residue at position 147 is N or Q, the residue at position 329 is D or E, the residue at position 347 is G or Q, or any combination thereof. In one embodiment, the residue at position 148 is K, R or H, the residue at position 151 is E, N or Q, the residue at position 245 is S, T, I, L, A, W, Y, P, V, or G, or any combination thereof. In one embodiment, the residue at position 148 is K, R or H, the residue at position 151 is E, N or Q, the residue at position 245 is S, T, I, L, A, or V, or any combination thereof. In one embodiment, the selected NA viral segment does not encode a NA having an aspartic acid at position 147, does not encode a NA having a threonine at position 148, does not encode a NA having an aspartic acid at position 151, does not encode a NA having an asparagine at position 245, does not encode a NA having an asparagine or threonine at residue 329, does not encode a NA having a glycine at position 346, does not encode a NA having a histidine, arginine or an asparagine at residue 347, or any combination thereof. In one embodiment the selected NA viral segment does not encode a NA having an aspartic acid at position 147, does not encode a NA having an asparagine at residue 329, does not encode a NA having a histidine, arginine or asparagine at residue 347, or any combination thereof. In one embodiment, the selected NA viral segment does not encode a NA having a threonine at position 148, does not encode a NA having an aspartic acid at position 151, does not encode a NA having an asparagine at position 245, does not encode a NA having a glycine at position 346, or any combination thereof. In one embodiment, the virus has HA H1, H3, H7, or H9. In one embodiment, the virus is an influenza A virus. In one embodiment, the virus comprises PA, PB1, PB2, NP, M, and NS viral segments with at least 85% nucleic acid sequence identity to SEQ ID Nos. 24 to 29 or 39 to 44 or encode a polypeptide having at least 80% amino acid sequence identity to a polypeptide encoded by SEQ ID Nos. 24 to 29 or 39 to 44. In one embodiment, the virus comprises PB2 having I, A, L, or G at residue 147.

[0133] In one embodiment, an isolated recombinant nucleic acid is provided comprising a nucleic acid sequence for an influenza virus NA viral segment that encodes a NA having a plurality of selected residues or a deletion of residues, wherein the NA viral segment does not encode a NA having a threonine at residue 32, does not encode a NA having an aspartic acid at position 147, does not encode a NA having a threonine at position 148, does not encode a NA having an aspartic acid at position 151, does not encode a NA having an asparagine at position 245, does not encode a NA having an asparagine or a threonine at residue 329, does not encode a NA having a histidine, arginine or asparagine at residue 347, or encodes a NA having a deletion of one or more of residues 46 to 50, or any combination thereof, wherein the numbering is based on N2. In one embodiment, the NA has at least 90% amino acid sequence identity to SEQ ID NO:1 or SEQ ID NO:3. In one embodiment, the NA has at least 90% amino acid sequence identity to SEQ ID NO:2. In one embodiment, the NA is a N2, N3, N7, or N9. In one embodiment, the NA is a N1, N4, N5, N6, N8, N10 or N11. In one embodiment, the residue at position 32 is A, I, G, or L. In one embodiment, the residue at position 147 is N or Q. In one embodiment, the residue at position 329 is D or E. In one embodiment, the residue at position 151 is E, N or Q. In one embodiment, the residue at position 148 is K, R or H. In one embodiment, the residue at position 245 is S, T, I, L, A, W, Y, P, V, or G. In one embodiment, the residue at position 347 is G, Q, S, or T.

[0134] In one embodiment, a method to prepare influenza virus is provided. The method includes contacting a cell with: a vector for vRNA production comprising a promoter operably linked to an influenza virus PA DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus PB1 DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus PB2 DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus HA DNA linked to a

transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus NP DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus NA DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus M DNA linked to a transcription termination sequence, and a vector for vRNA production comprising a promoter operably linked to an influenza virus NS DNA linked to a transcription termination sequence, wherein the PB1, PB2, PA, NP, NS, and M DNAs in the vectors for vRNA production are from one or more influenza vaccine virus isolates, wherein the NA DNA in the vector for vRNA production encodes a NA having a plurality of selected residues or a deletion of residues, wherein the NA does not encode a NA having a threonine at residue 32, does not encode a NA having an aspartic acid at position 147, does not encode a NA having a threonine at position 148, does not encode a NA having an aspartic acid at position 151, does not encode a NA having an asparagine at position 245, does not encode a NA having an asparagine at residue 329, does not encode a NA having a glycine at position 346, does not encode a NA having a histidine at residue 347, or encodes a NA having a deletion of one or more of residues 46 to 50, or any combination thereof, wherein the numbering for NA residues is that for N2; and a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus PA, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus PB1, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus PB2, and a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus NP, and optionally a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus HA, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus NA, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus M1, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus M2, or a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus NS2; in an amount effective to yield infectious influenza virus. In one embodiment, the NA has at least 90% amino acid to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:48, or SEQ ID NO:49. In one embodiment, the NA is N2, N3, N7, or N9. In one embodiment, the residue at position 147 is N or Q. In one embodiment, the residue at position 329 is D or E. In one embodiment, the residue at position 347 is Q, N, S, T, Y, C or W. In one embodiment, the residue at position 151 is E, N or Q. In one embodiment, the residue at position 148 is K, R or H. In one embodiment, the residue at position 245 is S, T, I, L, A, N, W, Y, P, V, or G. In one embodiment, the virus HA is H1, H3, H7, or H9. In one embodiment, The PA, PB1, PB2, NP, M, and NS viral segments have at least 85% nucleic acid sequence identity to SEQ ID Nos. 24 to 29 or 39 to 44 or encode a polypeptide having at least 80% amino acid sequence identity to a polypeptide encoded by SEQ ID Nos. 24 to 29 or 39 to 44. In one embodiment, HA is H2, H4, H5, H6, H8, or any of H10-H18. In one embodiment, virus prepared by the method is isolated. In one embodiment, virus is passaged through avian eggs.

[0135] In one embodiment, a method of immunizing an avian or a mammal is provided. The method includes administering to the avian or the mammal, e.g., a bovine, ovine, caprine, feline, canine, equine or human, a composition having an effective amount of the virus described above. In one embodiment, the composition comprises at least one other different influenza virus. In one embodiment, the composition is administered intranasally or via injection.

[0136] The invention will be described by the following non-limiting examples.

#### Example 1

[0137] Exemplary viral sequences for a master vaccine strain (PR8UW)

TABLE-US-00005 HA (SEQ ID NO: 22)

AGCAAAAGCAGGGGAAAATAAAAACAACCAAAATGAAGGCAAACCTACTGG

TCCTGTTATGTCAGCTGCAGATGCGAGACACAATATGTATAGGCTAC  
CATGCGAACAATTCAACCGACACTGTTGACACAGTACTCGAGAAGAATGTGA  
CAGTGACACACTCTGTTAACCTGCTCGAAGACAGCCACAACGGAAAACCTATG  
TAGATTAAAAGGAATAGCCCCACTACAATTGGGGAAATGTAACATCGCCGGA  
TGGCTCTTGGGAAACCCAGAATGCGACCCACTGCTTCCAGTGAGATCATGGT  
CCTACATTGTAGAAACACCAAACCTCTGAGAATGGAATATGTTATCCAGGAGA  
TTTCATCGACTATGAGGAGCTGAGGGAGCAATTGAGCTCAGTGTTCATCATT  
GAAAGATTCGAAATATTTCCCAAAGAAAGCTCATGGCCCAACCACAACACAA  
ACGGAGTAACGGCAGCATGCTCCCATGAGGGGAAAAGCAGTTTTTTACAGAAA  
TTTGCTATGGCTGACGGAGAAGGAGGGGCTCATACCCAAAGCTGAAAAATTCT  
TATGTGAACAAAAAAGGGAAAGAAGTCCTTGTACTGTGGGGTATTCATCACC  
CGCCTAACAGTAAGGAACAACAGAATCTCTATCAGAATGAAAATGCTTATGT  
CTCTGTAGTGACTTCAAATTATAACAGGAGATTTACCCCGGAAATAGCAGAA  
AGACCCAAAGTAAGAGATCAAGCTGGGAGGATGAACTATTACTGGACCTTGC  
TAAAACCCGGAGACACAATAATATTTGAGGCCAATGGAAATCTAATAGCACC  
AATGTATGCTTTTCGCACTGAGTAGAGGCTTTGGGTCCGGCATCATCACCTCAA  
ACGCATCAATGCATGAGTGTAACACGAAGTGTCAAACACCCCTGGGAGCTAT  
AAACAGCAGTCTCCCTTACCAGAATATACACCCAGTCACAATAGGAGAGTGC  
CCAAAATACGTCAGGAGTGCCAAATTGAGGATGGTTACAGGACTAAGGAAC  
ATTCCGTCCATTCAATCCAGAGGTCTATTTGGAGCCATTGCCGGTTTTATTGA  
AGGGGGATGGACTGGAATGATAGATGGATGGTATGGTTATCATCATCAGAAT  
GAACAGGGATCAGGCTATGCAGCGGATCAAAAAAGCACACAAAATGCCATT  
AACGGGATTACAAACAAGGTGAACACTGTTATCGAGAAAATGAACATTCAAT  
TCACAGCTGTGGGTAAAGAATTCAACAAATTAGAAAAAAGGATGGAAAATTT  
AAATAAAAAAGTTGATGATGGATTTCTGGACATTTGGACATATAATGCAGAA  
TTGTTAGTTCTACTGGAAAATGAAAGGACTCTGGATTTCCATGACTCAAATGT  
GAAGAATCTGTATGAGAAAGTAAAAAGCCAATTAAAGAATAATGCCAAAGA  
AATCGGAAATGGATGTTTTGAGTTCTACCACAAGTGTGACAATGAATGCATG  
GAAAGTGTAAGAAATGGGACTTATGATTATCCCAAATATTCAGAAGAGTCAA  
AGTTGAACAGGGAAAAGGTAGATGGAGTGAAATTGGAATCAATGGGGATCT  
ATCAGATTCTGGCGATCTACTCAACTGTCGCCAGTTCCTGCTTTTGGTC  
TCCCTGGGGGCAATCAGTTTCTGGATGTGTTCTAATGGATGTTTGCAGTGCAG  
AATATGCATCTGAGATTAGAATTTAGAGATATGAGGAAAAACACCCTTGTT TCTACT  
NA (SEQ ID NO: 23)

AGCAAAAGCAGGGGTTTAAAATGAATCCAAATCAGAAAATAATAACCATTG  
GATCAATCTGTCTGGTAGTCGGACTAATTAGCCTAATATTGCAAATAGGGAA  
TATAATCTCAATATGGATTAGCCATTCAATTCAAACTGGAAGTCAAAACCAT  
ACTGGAATATGCAACCAAAAACATCATTACCTATAAAAATAGCACCTGGGTAA  
AGGACACAACCTTCAGTGATATTAACCGGCAATTCATCTCTTTGTCCCATCCGT  
GGGTGGGCTATATACAGCAAAGACAATAGCATAAGAATTGGTTCCAAAGGA  
GACGTTTTTTGTCATAAGAGAGCCCTTTATTTTCATGTTCTCACTTGGAATGCAG  
GACCTTTTTTTCTGACCCAAGGTGCCTTACTGAATGACAAGCATTCAAGTGGGA  
CTGTTAAGGACAGAAGCCCTTATAGGGCCTTAATGAGCTGCCCTGTCGGTGA  
AGCTCCGTCCCCGTACAATTCAAGATTTGAATCGGTTGCTTGGTCAGCAAGTG  
CATGTCATGATGGCATGGGCTGGCTAACAATCGGAATTCAGGTCCAGATAA  
TGGAGCAGTGGCTGTATTAATAACAACGGCATAATACTGAAACCATAAAA  
AGTTGGAGGAAGAAAATATTGAGGACACAAGAGTCTGAATGTGCCTGTGTAA  
ATGGTTCATGTTTTACTATAATGACTGATGGCCCGAGTGATGGGCTGGCCTCG  
TACAAAATTTTCAAGATCGAAAAGGGGAAGGTTACTAAATCAATAGAGTTGA  
ATGCACCTAATTCTCACTATGAGGAATGTTCTGTTACCCTGATACCGGCAAA

GTGATGTGTGTGTGTCAGACAGACAGGTCGATCCGCGGCGGTGT  
 CTTTCGATCAAAACCTGGATTATCAAATAGGATACATCTGCAGTGGGGTTTTTC  
 GGTGACAACCCGCGTCCCGAAGATGGAACAGGCAGCTGTGGTCCAGTGTATG  
 TTGATGGAGCAAACGGAGTAAAGGGATTTTCATATAGGTATGGTAATGGTGT  
 TTGGATAGGAAGGACCAAAAAGTCACAGTTCCAGACATGGGTTTGAGATGATT  
 TGGGATCCTAATGGATGGACAGAGACTGATAGTAAGTTCTCTGTGAGGCAAG  
 ATGTTGTGGCAATGACTGATTGGTCAGGGTATAGCGGAAGTTTCGTTCAACAT  
 CCTGAGCTGACAGGGCTAGACTGTATGAGGCCGTGCTTCTGGGTTGAATTAA  
 TCAGGGGACGACCTAAAGAAAAAACAATCTGGACTAGTGCGAGCAGCATTTTC  
 TTTTGTGGCGTGAATAGTGATACTGTAGATTGGTCTTGGCCAGACGGTGCTG  
 AGTTGCCATTCAGCATTGACAAGTAGTCTGTTCAAAAAACTCCTTGTTTCTAC T PA  
 (SEQ ID NO: 24)AGCGAAAGCA GGTACTGATC CAAAATGGAA  
 GATTTTGTGC GACAATGCTT CAATCCGATG ATTGTCGAGC TTGCGGAAAA  
 AACAATGAAA GAGTATGGGG AGGACCTGAA AATCGAAACA AACAAATTTG  
 CAGCAATATG CACTCACTTG GAAGTATGCT TCATGTATTC AGATTTTTCAC  
 TTCATCAATG AGCAAGGCGA GTCAATAATC GTAGAACTTG GTGATCCAAA  
 TGCACTTTTG AAGCACAGAT TTGAAATAAT CGAGGGAAGA GATCGCACAA  
 TGGCCTGGAC AGTAGTAAAC AGTATTTGCA AACTACAGG GGCTGAGAAA  
 CCAAAGTTTC TACCAGATTT GTATGATTAC AAGGAGAATA GATTCATCGA  
 AATTGGAGTA ACAAGGAGAG AAGTTCACAT ATACTATCTG GAAAAGGCCA  
 ATAAAATTAA ATCTGAGAAA ACACACATCC ACATTTTCTC GTTCACTGGG  
 GAAGAAATGG CCACAAAGGC AGACTACACT CTCGATGAAG AAAGCAGGGC  
 TAGGATCAAA ACCAGACTAT TCACCATAAG ACAAGAAATG GCCAGCAGAG  
 GCCTCTGGGA TTCCTTTCGT CAGTCCGAGA GAGGAGAAGA GACAATTGAA  
 GAAAGGTTTG AAATCACAGG AACAATGCGC AAGCTTGCCG ACCAAAGTCT  
 CCCGCCGAAC TTCTCCAGCC TTGAAAATTT TAGAGCCTAT GTGGATGGAT  
 TCGAACCGAA CGGCTACATT GAGGGCAAGC TGTCTCAAAT GTCCAAAGAA  
 GTAAATGCTA GAATTGAACC TTTTTTGAAA ACAACACCAC GACCACTTAG  
 ACTTCCGAAT GGGCCTCCCT GTTCTCAGCG GTCCAAATTC CTGCTGATGG  
 ATGCCTTAAA ATTAAGCATT GAGGACCCAA GTCATGAAGG AGAGGGAATA  
 CCGCTATATG ATGCAATCAA ATGCATGAGA ACATTCTTTG GATGGAAGGA  
 ACCCAATGTT GTTAAACCAC ACGAAAAGGG AATAAATCCA AATTATCTTC  
 TGTCATGGAA GCAAGTACTG GCAGAACTGC AGGACATTGA GAATGAGGAG  
 AAAATTCCAA AGACTAAAAA TATGAAGAAA ACAAGTCAGC TAAAGTGGGC  
 ACTTGGTGAG AACATGGCAC CAGAAAAGGT AGACTTTGAC GACTGTAAAG  
 ATGTAGGTCA TTTGAAGCAA TATGATAGTG ATGAACCAGA ATTGAGGTCTG  
 CTTGCAAGTT GGATTCAGAA TGAGTTTAAC AAGGCATGCG AACTGACAGA  
 TTCAAGCTGG ATAGAGCTCG ATGAGATTGG AGAAGATGTG GCTCCAATTG  
 AACACATTGC AAGCATGAGA AGGAATTATT TCACATCAGA GGTGTCTCAC  
 TGCAGAGCCA CAGAATACAT AATGAAGGGA GTGTACATCA ATACTGCCTT  
 GCTTAATGCA TCTTGTGCAG CAATGGATGA TTTCCAATTA ATTCCAATGA  
 TAAGCAAGTG TAGAACTAAG GAGGGAAGGC GAAAGACCAA CTTGTATGGT  
 TTCATCATAA AAGGAAGATC CCACTTAAGG AATGACACCG ACGTGGTAAA  
 CTTTGTGAGC ATGGAGTTTT CTCTCACTGA CCCAAGACTT GAACCACATA  
 AATGGGAGAA GTACTGTGTT CTTGAGATAG GAGATATGCT TATAAGAAGT  
 GCCATAGGCC AGGTTTCAAG GCCCATGTTC TTGTATGTGA GAACAAATGG  
 AACCTCAAAA ATTAAAATGA AATGGGGAAT GGAGATGAGG CGTTGCCTCC  
 TCCAGTCACT TCAACAAATT GAGAGTATGA TTGAAGCTGA GTCCTCTGTC  
 AAAGAGAAAG ACATGACCAA AGAGTTCTTT GAGAACAAAT CAGAAACATG  
 GCCCATTGGA GAGTCCCCCA AAGGAGTGGA GGAAAGTTCC ATTGGGAAGG

TCTGCAGGAC TTTATTAGCA AAGTCCGGTAT TCAACAGCTT GTATCATGCT  
CCACAAC TAG AAGGATTTTC AGCTGAATCA AGAAAAC TGC TTCTTATCGT  
TCAGGCTCTT AGGGACAACC TGGAACCTGG GACCTTTGAT CTTGGGGGGC  
TATATGAAGC AATTGAGGAG TGCCTGATTA ATGATCCCTG GGTTTTGCTT  
AATGCTTCTT GGTTCAACTC CTTCTTACA CATGCATTGA GTTAGTTGTG  
GCAGTGCTAC TATTTGCTAT CCATACTGTC CAAAAAAGTA CCTTGTTTCT ACT  
PB1 (SEQ ID NO: 25)

AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACCTTACTTTTCTT  
AAAAGTGCCAGCACAAAATGCTATAAGCACAACTTTCCCTTATACTGGAGAC  
CCTCCTTACAGCCATGGGACAGGAACAGGATACACCATGGATACTGTCAACA  
GGACACATCAGTACTCAGAAAAGGGAAGATGGACAACAAACACCGAACTG  
GAGCACCGCAACTCAACCCGATTGATGGGCCACTGCCAGAAGACAATGAACC  
AAGTGGTTATGCCCAAACAGATTGTGTATTGGAGGCGATGGCTTTCCTTGAG  
GAATCCCATCCTGGTATTTTTTGAAAAC TCGTGTATTGAAACGATGGAGGTTGT  
TCAGCAAACACGAGTAGACAAGCTGACACAAGGCCGACAGACCTATGACTG  
GACTCTAAATAGAAACCAACCTGCTGCAACAGCATTGGCCAACACAATAGAA  
GTGTTT CAGATCAAATGGCCTCACGGCCAATGAGTCTGGAAGGCTCATAGACT  
TCCTTAAGGATGTAATGGAGTCAATGAACAAAGAAGAAATGGGGATCACAA  
CTCATTTTCAGAGAAAGAGACGGGTGAGAGACAATATGACTAAGAAAATGAT  
AACACAGAGAACAAATGGGTAAAAAGAAGCAGAGATTGAACAAAAGGAGTTA  
TCTAATTAGAGCATTGACCCTGAACACAATGACCAAAGATGCTGAGAGAGGG  
AAGCTAAAACGGAGAGCAATTGCAACCCCGAGGATGCAAATAAGGGGGTTT  
GTATACTTTGTTGAGACACTGGCAAGGAGTATATGTGAGAACTTGAACAAT  
CAGGGTTGCCAGTTGGAGGCAATGAGAAGAAAGCAAAGTTGGCAAATGTTGT  
AAGGAAGATGATGACCAATTCTCAGGACACCGAACTTTCTTTCACCATCACT  
GGAGATAACACCAAATGGAACGAAAATCAGAATCCTCGGATGTTTTTGGCCA  
TGATCACATATATGACCAGAAATCAGCCCGAATGGTTCAGAAATGTTCTAAG  
TATTGCTCCAATAATGTTCTCAAACAAAATGGCGAGACTGGGAAAAGGGTAT  
ATGTTTGAGAGCAAGAGTATGAACTTAGAACTCAAATACCTGCAGAAATGC  
TAGCAAGCATCGATTTGAAATATTTCAATGATTCAACAAGAAAGAAGATTGA  
AAAAATCCGACCGCTCTTAATAGAGGGGACTGCATCATTGAGCCCTGGAATG  
ATGATGGGCATGTTCAATATGTTAAGCACTGTATTAGGCGTCTCCATCCTGAA  
TCTTGGAACAAAAGAGATACACCAAGACTACTTACTGGTGGGATGGTCTTCAA  
TCCTCTGACGATTTTGCTCTGATTGTGAATGCACCCAATCATGAAGGGATTCA  
AGCCGGAGTCGACAGGTTTTATCGAACCTGTAAGCTACTTGGAATCAATATG  
AGCAAGAAAAAGTCTTACATAAACAGAACAGGTACATTTGAATTCACAAGTT  
TTTTCTATCGTTATGGGTTTGTTGCCAATTT CAGCATGGAGCTTCCCAGTTTTG  
GGGTGTCTGGGATCAACGAGTCAGCGGACATGAGTATTGGAGTTACTGT CAT  
CAAAAACAATATGATAAACAAATGATCTTGGTCCAGCAACAGCTCAAATGGCC  
CTTCAGTTGTT CATCAAAGATTACAGGTACACGTACCGATGCCATATAGGTGA  
CACACAAATACAAACCCGAAGATCATTTGAAATAAAGAACTGTGGGAGCA  
AACCCGTTCCAAAGCTGGACTGCTGGTCTCCGACGGAGGCCCAAATTTATAC  
AACATTAGAAATCTCCACATTCCTGAAGTCTGCCTAAAATGGGAATTGATGG  
ATGAGGATTACCAGGGGCGTTTATGCAACCCACTGAACCCATTTGTCAGCCA  
TAAAGAAATTGAATCAATGAACAATGCAGTGATGATGCCAGCACATGGTCCA  
GCCAAAAACATGGAGTATGATGCTGTTGCAACAACACACTCCTGGATCCCCA  
AAAGAAATCGATCCATCTTGAATACAAGTCAAAGAGGAGTACTTGAGGATGA  
ACAAATGTACCAAAGGTGCTGCAATTTATTTGAAAAATTCTTCCCCAGCAGTT  
CATACAGAAGACCAGTCGGGATATCCAGTATGGTGGAGGCTATGGTTTCCAG  
AGCCCGAATTGATGCACGGATTGATTTCGAATCTGGAAGGATAAAGAAAGAA

GAGTTCTGATGATCATGATGATCTGTTCCACCATTAAGTAGTACGACGCGC  
AAAAATAGTGAATTTAGCTTGTCTTCATGAAAAAATGCCTTGTTTCTACT PB2 (SEQ  
ID NO: 26) AGCGAAAGCA GGTCAATTAT ATTCAATATG GAAAGAATAA  
AAGAACTACG AAATCTAATG TCGCAGTCTC GCACCCGCGA GATACTCACA  
AAAACCACCG TGGACCATAT GGCCATAATC AAGAAGTACA CATCAGGAAG  
ACAGGAGAAG AACCCAGCAC TTAGGATGAA ATGGATGATG GCAATGAAAT  
ATCCAATTAC AGCAGACAAG AGGATAACGG AAATGATTCC TGAGAGAAAT  
GAGCAAGGAC AAAC TTTATG GAGTAAAATG AATGATGCCG GATCAGACCG  
AGTGATGGTA TCACCTCTGG CTGTGACATG GTGGAATAGG AATGGACCAA  
TAACAAATAC AGTTCATTAT CCAAAAATCT ACAA AACTTA TTTTGAAAGA  
GTCGAAAGGC TAAAGCATGG AACCTTTGGC CCTGTCCATT TTAGAAACCA  
AGTCAAAATA CGTCGGAGAG TTGACATAAA TCCTGGTCAT GCAGATCTCA  
GTGCCAAGGA GGCACAGGAT GTAATCATGG AAGTTGTTTT CCCTAACGAA  
GTGGGAGCCA GGATACTAAC ATCGGAATCG CAACTAACGA TAACCAAAGA  
GAAGAAAGAA GAACTCCAGG ATTGCAAAAT TTCTCCTTTG ATGGTTGCAT  
ACATGTTGGA GAGAGA ACTG GTCCGCAAAA CGAGATTCCT CCCAGTGGCT  
GGTGGAACAA GCAGTGTGTA CATTGAAGTG TTGCATTGTA CTCAAGGAAC  
ATGCTGGGAA CAGATGTATA CTCCAGGAGG GGAAGTGAGG AATGATGATG  
TTGATCAAAG CTTGATTATT GCTGCTAGGA ACATAGTGAG AAGAGCTGCA  
GTATCAGCAG ATCCACTAGC ATCTTTATTG GAGATGTGCC ACAGCACACA  
GATTGGTGGA ATTAGGATGG TAGACATCCT TAGGCAGAAC CCAACAGAAG  
AGCAAGCCGT GGATATATGC AAGGCTGCAA TGGGACTGAG AATTAGCTCA  
TCCTTCAGTT TTGGTG GATT CACATTTAAG AGAACAAGCG GATCATCAGT  
CAAGAGAGAG GAAGAGGTGC TTACGGGCAA TCTTCAAACA TTGAAGATAA  
GAGTGCATGA GGGATATGAA GAGTTCACAA TGGTTGGGAG AAGAGCAACA  
GCCATACTCA GAAAAGCAAC CAGGAGATTG ATTCAGCTGA TAGTGAGTGG  
GAGAGACGAA CAGTCGATTG CCGAAGCAAT AATTGTGGCC ATGGTATTTT  
CACAAGAGGA TTGTATGATA AAAGCAGTCA GAGGTGATCT GAATTTCTGTC  
AATAGGGCGA ATCAACGATT GAATCCTATG CATCAACTTT TAAGACATTT  
TCAGAAGGAT GCGAAAGTGC TTTTTC AAAA TTGGGGGAGTT GAACCTATCG  
ACAATGTGAT GGG AATGATT GGGATATTGC CCGACATGAC TCCAAGCATC  
GAGATGTCAA TGAGAGGAGT GAGAATCAGC AAAATGGGTG TAGATGAGTA  
CTCCAGCACG GAGAGGGTAG TGGTGAGCAT TGACCGTTTT TTGAGAATCC  
GGGACCAACG AGGAAATGTA CTACTGTCTC CCGAGGAGGT CAGTGAAACA  
CAGGGAACAG AGAACTGAC AATAACTTAC TCATCGTCAA TGATGTGGGA  
GATTAATGGT CCTGAATCAG TGTTGGTCAA TACCTATCAA TGGATCATCA  
GAAACTGGGA AACTGT TAAA ATTCAGTGGT CCCAGAACCC TACAATGCTA  
TACAATAAAA TGGAATTTGA ACCATTT CAG TCTTTAGTAC CTAAGGCCAT  
TAGAGGCCAA TACAGTGGGT TTGTAAGAAC TCTGTTCCAA CAAATGAGGG  
ATGTGCTTGG GACATTTGAT ACCGCACAGA TAATAAACT TCTTCCCTTC  
GCAGCCGCTC CACCAAAGCA AAGTAGAATG CAGTTCTCCT CATT TACTGT  
GAATGTGAGG GGATCAGGAA TGAGAATACT TGTAAGGGGC AATTCTCCTG  
TATTCAACTA TAACAAGGCC ACGAAGAGAC TCACAGTTCT CGGAAAGGAT  
GCTGGCACTT TAACTGAAGA CCCAGATGAA GGCACAGCTG GAGTGGAGTC  
CGCTGTTCTG AGGGGATTCC TCATTCTGGG CAAAGAAGAC AAGAGATATG  
GGCCAGCACT AAGCATCAAT GAACTGAGCA ACCTTGCGAA AGGAGAGAAG  
GCTAATGTGC TAATTGGGCA AGGAGACGTG GTGTTGGTAA TGAAACGGAA  
ACGGGACTCT AGCATACTTA CTGACAGCCA GACAGCGACC AAAAGAATTC  
GGATGGCCAT CAATTAGTGT CGAATAGTTT AAAAACGACC TTGTTTCTAC T  
NP (SEQ ID NO: 27) AGCAAAAGCA GGGTAGATAA TCACTCACTG

AGTGACATCA	AAATCATGCG GTCTCAAGGC	ACCAACACGAT	CTTACGAACA
GATGGAGACT	GATGGAGAAC GCCAGAATGC	CACTGAAATC	AGAGCATCCG
TCGGAAAAAT	GATTGGTGA ATTGGACGAT	TCTACATCCA	AATGTGCACC
GAAGTCAAAC	TCAGTGATTA TGAGGGACGG	TTGATCCAAA	ACAGCTTAAC
AATAGAGAGA	ATGGTGCTCT CTGCTTTTGA	CGAAAGGAGA	AATAAATACC
TTGAAGAACA	TCCCAGTGCG GGGAAAGATC	CTAAGAAAAC	TGGAGGACCT
ATATACAGGA	GAGTAAACGG AAAGTGGATG	AGAGAACTCA	TCCTTTATGA
CAAAGAAGAA	ATAAGGCGAA TCTGGCGCCA	AGCTAATAAT	GGTGACGATG
CAACGGCTGG	TCTGACTCAC ATGATGATCT	GGCATTCCAA	TTTGAATGAT
GCAACTTATC	AGAGGACAAG AGCTCTTGTT	CGCACCGGAA	TGGATCCCAG
GATGTGCTCT	CTGATGCAAG GTTCAACTCT	CCCTAGGAGG	TCTGGAGCCG
CAGGTGCTGC	AGTCAAAGGA GTTGGAACAA	TCGTGATGGA	ATTGGTCAGA
ATGATCAAAC	GTGGGATCAA TGATCGGAAC	TTCTGGAGGG	GTGAGAATGG
ACGAAAAACA	AGAATTGCTT ATGAAAGAAT	GTGCAACATT	CTCAAAGGGA
AATTTCAAAC	TGCTGCACAA AAAGCAATGA	TGGATCAAGT	GAGAGAGAGC
CGGAACCCAG	GGAATGCTGA GTTCGAAGAT	CTCACTTTTC	TAGCACGGTC
TGCACTCATA	TTGAGAGGGT CGGTTGCTCA	CAAGTCCTGC	CTGCCTGCCT
GTGTGTATGG	ACCTGCCGTA GCCAGTGGGT	ACGACTTTGA	AAGGGAGGGA
TACTCTCTAG	TCGGAATAGA CCCTTTCAGA	CTGCTTCAAA	ACAGCCAAGT
GTACAGCCTA	ATCAGACCAA ATGAGAATCC	AGCACACAAG	AGTCAACTGG
TGTGGATGGC	ATGCCATTCT GCCGCATTTG	AAGATCTAAG	AGTATTAAGC
TTCATCAAAG	GGACGAAGGT GCTCCCAAGA	GGGAAGCTTT	CCACTAGAGG
AGTTCAAATT	GCTTCCAATG AAAATATGGA	GACTATGGAA	TCAAGTACAC
TTGAACTGAG	AAGCAGGTAC TGGGCCATAA	GGACCAGAAG	TGGAGGAAAC
ACCAATCAAC	AGAGGGCATC TGCGGGCCAA	ATCAGCATAC	AACCTACGTT
CTCAGTACAG	AGAAATCTCC CTTTTGACAG	AACAACCATT	ATGGCAGCAT
TCAATGGGAA	TACAGAGGGG AGAACATCTG	ACATGAGGAC	CGAAATCATA
AGGATGATGG	AAAGTGCAAG ACCAGAAGAT	GTGTCTTTCC	AGGGGCGGGG
AGTCTTCGAG	CTCTCGGACG AAAAGGCAGC	GAGCCCGATC	GTGCCTTCCT
TTGACATGAG	TAATGAAGGA TCTTATTTCT	TCGGAGACAA	TGCAGAGGAG
TACGACAATT	AAAGAAAAAT ACCCTTGTTT	CTACT M (SEQ ID NO: 28)	
AGCAAAAGCA	GGTAGATATT GAAAGATGAG	TCTTCTAACC	GAGGTCGAAA
CGTACGTACT	CTCTATCATC CCGTCAGGCC	CCCTCAAAGC	CGAGATCGCA
CAGAGACTTG	AAGATGTCTT TGCAGGGAAG	AACACCGATC	TTGAGGTTCT
CATGGAATGG	CTAAAGACAA GACCAATCCT	GTCACCTCTG	ACTAAGGGGA
TTTTAGGATT	TGTGTTACAG CTCACCGTGC	CCAGTGAGCG	AGGACTGCAG
CGTAGACGCT	TTGTCCAAAA TGCCCTTAAT	GGGAACGGGG	ATCCAAATAA
CATGGACAAA	GCAGTTAAAC TGTATAGGAA	GCTCAAGAGG	GAGATAACAT
TCCATGGGGC	CAAAGAAATC TCACTCAGTT	ATTCTGCTGG	TGCACTTGCC
AGTTGTATGG	GCCTCATATA CAACAGGATG	GGGGCTGTGA	CCACTGAAGT
GGCATTGCG	CTGGTATGTG CAACCTGTGA	ACAGATTGCT	GACTCCCAGC
ATCGGTCTCA	TAGGCAAATG GTGACAACAA	GCAATCCACT	AATCAGACAT
GAGAACAGAA	TGGTTTTAGC CAGCACTACA	GCTAAGGCTA	TGGAGCAAAT
GGCTGGATCG	AGTGAGCAAG CAGCAGAGGC	CATGGAGGTT	GCTAGTCAGG
CTAGACAAAT	GGTGCAAGCG ATGAGAACCA	TTGGGACTCA	TCCTAGCTCC
AGTGCTGGTC	TGAAAAATGA TCTTCTTGAA	AATTTGCAGG	CCTATCAGAA
ACGAATGGGG	GTGCAGATGC AACGGTTCAA	GTGATCCTCT	CACTATTGCC
GCAAATATCA	TTGGGATCTT GCACTTGACA	TTGTGGATTG	TTGATCGTCT
TTTTTTCAA	TGCATTTACC GTCGCTTTAA	ATACGGACTG	AAAGGAGGGC
CTTCTACGGA	AGGAGTGCCA AAGTCTATGA	GGGAAGAATA	TCGAAAGGAA



CAGCAGAGTG	CTGTGGATGC	TGACGATGGT	CATTTGTCA	GCATAGAGCT
GGAGTAAAAA	ACTACCTTGT	TTCTACT NS (SEQ ID NO: 29)	AGCAAAAGCA	
GGGTGACAAA	AACATAATGG	ATCCAAACAC	TGTGTCAAGC	TTTCAGGTAG
ATTGCTTTCT	TTGGCATGTC	CGCAAACGAG	TTGCAGACCA	AGAAGTAGGC
GATGCCCCAT	TCCTTGATCG	GCTTCGCCGA	GATCAGAAAT	CCCTAAGAGG
AAGGGGCAGT	ACTCTCGGTC	TGGACATCAA	GACAGCCACA	CGTGCTGGAA
AGCAGATAGT	GGAGCGGATT	CTGAAAGAAG	AATCCGATGA	GGCACTTAAA
ATGACCATGG	CCTCTGTACC	TGCGTCGCGT	TACCTAACTG	ACATGACTCT
TGAGGAAATG	TCAAGGGACT	GGTCCATGCT	CATACCCAAG	CAGAAAGTGG
CAGGCCCTCT	TTGTATCAGA	ATGGACCAGG	CGATCATGGA	TAAGAACATC
ATACTGAAAG	CGAACTTCAG	TGTGATTTTT	GACCGGCTGG	AGACTCTAAT
ATTGCTAAGG	GCTTTCACCG	AAGAGGGAGC	AATTGTTGGC	GAAATTTTAC
CATTGCCTTC	TCTTCCAGGA	CATACTGCTG	AGGATGTCAA	AAATGCAGTT
GGAGTCCTCA	TCGGAGGACT	TGAATGGAAT	GATAACACAG	TTCGAGTCTC
TGAAACTCTA	CAGAGATTCTG	CTTGGAGAAG	CAGTAATGAG	AATGGGAGAC
CTCCACTCAC	TCCAAAACAG	AAACGAGAAA	TGGCGGGAAC	AATTAGGTCA
GAAGTTTGAA	GAAATAAGAT	GGTTGATTGA	AGAAGTGAGA	CACAAACTGA
AGATAACAGA	GAATAGTTTT	GAGCAAATAA	CATTTATGCA	AGCCTTACAT
CTATTGCTTG	AAGTGGAGCA	AGAGATAAGA	ACTTTCTCGT	TTCAGCTTAT
TTAGTACTAA	AAAACACCCT	TGTTTCTACT		

## Example 2

### Neuraminidase Modifications

#### Materials

[0138] Viruses: Y2017: A/Yokohama/2017/2003 (H3N2) [0139] HK4801: A/Hong Kong/4801/2014(H3N2) [0140] Y2017-M3L4: Y2017 passaged 7 times in eggs [0141] HY-PR8: high yield PR8 (H1N1)

#### Results

[0142] Y2017 virus was passaged 7 times in eggs (3 times in the amniotic cavity, followed by 4 times in the allantoic cavity). A progeny virus, Y2017-M3L4, grew efficiently in the allantoic cavity (10.sup.7 to about 10.sup.8 PFU/mL), whereas the original Y2017 virus did not grow at all (<10 PFU/mL).

[0143] Mutations observed in Y2017-M3L4 virus were as follows:

TABLE-US-00006 TABLE 1 PB2 NA NP M1 eggA T147I, V344L del 46-50aa, none E23Q and T174I, T32A, D147N, V344L, E358K N329D, H347Q eggB T147I del 46-50aa, D101N none T32A, D147N, N329D, H347Q eggC T147I del 46-50aa, D101N none T32A, D147N, N329D, H347Q

[0144] A comparison of the growth ability of mutant Y2017 viruses, generated by reverse genetics, in allantoic fluid revealed that NA mutations were responsible for the high growth of Y2017-M3L4 virus (FIG. 4). A plasmid with PB2-T147I was used for virus generation (PB2-T147I, V344L and PB2-T147I, V344L, E358K were not analyzed). Mutations were not observed in the HA gene of the virus possessing a mutated NA segment and its other genes from wild-type Y2017 after replication in allantoic fluid (FIG. 4).

[0145] FIG. 5 shows the location of the NA mutations in Y2017-M3L4 in a 3D model.

[0146] Comparison of the growth ability of Y2017 viruses with NA mutations revealed that NA-D147N, N329D, and H347Q generally contributed to the increased growth ability in allantoic fluid (FIG. 6).

[0147] The NA of Y2017-M3L4 allowed virus possessing HK4801HA to replicate efficiently in the allantoic cavity and the HY-PR8 backbone further enhanced the growth of this virus (FIG. 7).

[0148] In summary, described herein are influenza virus mutations that inhibit (e.g., prevent) the acquisition of antigenicity-compromising mutations in the hemagglutinin (HA) protein of influenza

during growth in eggs and/or allow for enhanced replication. In one embodiment, the mutations are within the neuraminidase (NA) viral segment of human influenza viruses, and the mutant NA proteins stabilize the HA protein during egg-passages. Thus, in the presence of the mutant NA proteins, the HA protein does not acquire egg-adapting mutations. In some cases, the respective mutations in NA can also increase the yield of vaccine viruses.

### Example 3

[0149] Analysis of the growth capability of NA mutant viruses revealed that NA-D147N, N329D, and H347Q contribute to the increased growth capability of the viruses in allantoic fluid (FIG. 12). HA mutations were not observed in the virus possessing HK4801HA, Y2017-M3L4NA, and the HY-PR8 backbone (FIG. 13) after 3 passages in the allantoic cavity.

[0150] By passaging an HY-PR8 backbone virus possessing HK4801NA (T148K and the saturated mutations N329X and H347X) and HK4801HA in eggs, a virus possessing HK4801NA (T148K, D151E, H347G, and T369K) emerged that replicated efficiently in the allantoic cavity (FIG. 14; 4M=T148K, D151E, H347G, and T369K). HA mutations were not observed during passages in eggs (1x in the amniotic cavity then 5x in the allantoic cavity).

[0151] HK4801NA (T148K, D151E, H347G, and T369K) conferred efficient replication in the allantoic cavity to HY-PR8 backbone viruses possessing either HK4801HA or Singapore0019HA. Virus inoculation:  $2 \times 10^{3.3}$  pfu/egg into allantoic fluid, 72 h incubation at 37° C. (FIG. 16).

[0152] The HA coding nucleic acid sequence and NA coding nucleic acid and amino acid sequences for Singapore0019 are as follows:

TABLE-US-00007 A/Singapore/INFINH-16-0019/2016(H3N2) HA (SEQ ID NO: 46)

atgaagactatcattgcttgagctacattctatgtctggttttcgctcaaaaattcctggaaatgacaatagcacggcaacgctgt  
gccttgggcacccatgcagtacaaacggaacgatagtgaaaacaatcacaaatgaccgaattgaagtactaatgctactgagtt  
gggtcagaattcctcaatagggtgaaatatgcgacagtcctcatcagatccttgatggagagaactgcacactaatagatgctctatt  
gggagaccctcagtgatggcttcaaaaataagaaatgggaccttttgtgaacgaagcaaaagcctacagcaactgttacctt  
atgatgtgccgattatgcctcccttaggtcactagttgcctcatccggcacactggagtttaaaaatgaaagcttcaattggactg  
gagtcactcaaaacggaacaagttctgcttgcataaggggatctagtagtagtttcttagtagattaaattgggtgaccacttaaa  
ctacacatatccagcattgaacgtgactatgccaaacaaggaacaatttgacaaattgtacatttgggggggtcaccacccgggta  
cggacaaggaccaaattcttctgtatgctcaatcatcaggaagaatcacagtatctacaaaagaagccaacaagctgtaatccc  
aaatatcggatctagaccagaataagggatatccctagcagaataagcatctattggacaatagtaaaaccgggagacatacttt  
tgattaacagcacagggaatctaattgctcctaggggttacttcaaaatacgaagtgggaaaagctcaataatgagatcagatgca  
cccattggcaaatgcaagtctgaatgcactccaaatggaagcattcccaatgacaaaccattccaaaatgtaaacaggatca  
catacggggcctgtcccagatatgttaagcatagcactctgaaattggcaacaggaatgcgaaatgtaccagagaaacaaacta  
gaggcatatttggcgcaatagcgggtttcatagaaaatggttgggaggggaatggtggatggttggtacgggttcaggcatcaaaa  
ttctgaggggaagaggacaagcagcagatctcaaaagcactcaagcagcaatcgatcaaatcaatgggaagctgaataggttga  
tcggaaaaaccaacgagaaattccatcagattgaaaaagaattctcagaagtagaaggaagagttcaagaccttgagaaatatgt  
tgaggacactaaaatagatctctggtcatacaacgcggagcttctgttgcctggagaaccaacatacaattgatctaactgactc  
agaaatgaacaaactgtttgaaaaaacaagaagcaactgagggaaaatgctgaggatatgggaaatggttgtttcaaaatatac  
cacaatgtgacaatgcctgcatagaatcaataagaaatgaaacttatgaccacaatgtgtacagggatgaagcattgaacaacc  
gggtccagatcaaggagttgagctgaagtcaggatacaaagattggatcctatggatttccttgccatatcatgtttttgctttgtg  
ttgctttgttgggttcatcatgtgggcctgcaaaaagggaacattagatgcaacattgcatttga A/Singapore/INFINH-16-  
0019/2016(H3N2) NA (SEQ ID NO: 47)

atgaatccaaatcaaaagataataacgattggctctgtttctctcaccatttcacaatatgcttctcatgcaaattgccatcctgata  
actactgtaacattgcatttcaagcaatatgaattcaactccccccaaacaaccaagtgtgctgtgtgaaccaacaataatagaa  
agaaacataacagagatagtgtatttgaccaacaccaccatagagaaggaaatatgccccaaaccagcagaatacagaaattg  
gtcaaaaccgcaatgtggcattacaggatttgacctttcttaaggacaattcgattaggctttccgctgggtggggacatctgggt  
gacaagagaaccttatgtgcatgcgatcctgacaagtgttatcaatttgccttggacaggggaacaacactaaacaacgtgcatt  
caaataacacagtacgtgataggacccttatcgactctattgatgaatgagttgggtgttcctttccatctggggaccaagcaag  
tgtgcatagcatggtccagctcaagttgtcacgatggaaaagcatggctgcatgtttgtataacgggggatgataaaaatgcaact  
gctagcttcattacaatgggaggcttatagatagttgtttcatggtccaaagatatctcaggaccaggagtcagaatgcgttt

gtatcaatggaactgtacagtagtaatgactgatggaaatgctacaggaaaagctgatactaaaatactattcattgaggagggg  
aaaatcggtcatactagcaaattgtcaggaagtgtcagcatgtcgaagagtgtcttgctatcctcgatatcctgggtgcagatgtg  
tctgcagagacaactggaaaggatccaaccggcccatcgtagatataaacataaaggatcatagcattgtttccagttatgtgtgtt  
caggactgttggagacacaccagaaaaaacgacagctccagcagtagccattgtttgaatcctaacaatgaagaagggtggtc  
atggagtgaaggctgggcctttgatgatggaaatgacgtgtggatggggagaacaatcaacgagacgtcacgcttagggat  
gaaaccttcaaagtcgttgaaggctgggtccaaccctaagtccaaattgcagataaattaggcaagtcatagttgacagaggtgata  
gggtccgggtattctggtattttctgttgaaggcaaaaagctgcatcaatcgggtgctttatgtggagttgattaggggaagaaaaga  
ggaaactgaagtcttgtggacctcaaacagtattgtgtgtttgtggcacctcaggtacatatggaacagggtcatggcctgatgg  
ggcggacctcaatctcatgcatatataa which encodes (SEQ ID NO: 48) M N P N Q K  
I I T I G S V S L T I S T I C F F M Q I A I L I T  
T V T L H F K Q Y E F N S P P N N Q V M L C E P  
T I I E R N I T E I V Y L T N T T I E K E I C P K  
P A E Y R N W S K P Q C G I T G F A P F S K D N  
S I R L S A G G D I W V T R E P Y V S C D P D K  
C Y Q F A L G Q G T T L N N V H S N N T V K D R  
T P Y R T L L M N E L G V P F H L G T K Q V C I  
A W S S S S C H D G K A W L H V C I T G D D K N  
A T A S F I Y N G R L I D S V V S W S K D I L R  
T Q E S E C V C I N G T C T V V M T D G N A T  
G K A D T K I L F I E E G K I V H R T S K L S G S  
A Q H V E E C S C Y P R Y P G V R C V C R D N W  
K G S N R P I V D I N I K D H S I V S S Y V C S  
G L V G D T P R K N D S S S S S H C L N P N N E  
E G G H G V K G W A F D D G N D V W M G R T I  
N E T S R L G Y E T F K V V E G W S N P K S K L  
Q I N R Q V I V D R G D R S G Y S G I F S V E G  
K S C I N R C F Y V E L I R G R K E E T E V L W  
T S N S I V V F C G T S G T Y G T G S W P D G A  
D L N L M H I.

[0153] NA mutations T153N, N329T, and T369K allowed A/Saitama/102/2014 (H3N2) to replicate efficiently in the allantoic cavity (Kuwahara et al., 2018). Therefore, the effect of introducing NA-T153N, N329T (or D), T369K, and H347Q into HK4801NA(T148K) was examined. FIG. 18 reports on virus titers for different combinations of NA residues identified in screenings. FIGS. 19 and 20 report on virus titers for viruses with different combinations of selected NA residues.

#### Example 4

[0154] A/Alaska/232/2015\_HY-PR8 (H3N2) WT/mutant virus were passaged in eggs and HA and NA segments sequenced. Alaska WT (a more recent H3N2 virus where WT has 245N, prior to 2015 H3N2 WT viruses had 245S), HA-R142S, -K189E viruses did not get mutations in HA, even after 3 amniotic and 10 allantoic passages. HA-K189E/N158K/A212T mutant did not get mutations in HA, but had some mutations in NA which exhibited improved growth in eggs since p6 (FIG. 21). The difference of NA mutations between p4 (normal growth) (NA-N245S mutation, virus grows more than 1000 fold better than with NA-245N) and p6 (better growth) was G346V (FIG. 22). Therefore, G346V may also contribute to adaptation to eggs.

The NA for A/Alaska/232/2015 has the following sequence:

TABLE-US-00008 (SEQ ID NO: 49) mnpnqkiiti gsvltisti cffmqiaili ttvthfkqy  
efnsppnnqv mlceptiier niteivyltn ttiekeicpk paeyrnwskp qcgitgfapf skdnsirlsa  
ggdiwvtrep yvscdpdkcy qfalgggttl nnvhsnntvr drtpyrllm nelgvpfhlg tkqvciawss  
sschdgdawl hvcitgddkn atasfiyngr lvdsrvswsk dilrtqesec vcingtctvv mtdgnatgka  
dtkilfieeg kivhtsklsg saqhveecsc yprypgvrcv crdnwksnr pivdinikdh sivssyvcsg  
lvgdtpkrnd ssssshclnp nneegghgvk gwafddgndv wmgtrinetis rlgyetfkvv egwsnpkskl

qinrqvivr gdrsgysgif svegkscinr cfyvelirgr keetevlwts nsivvfcgts gtygtgswpd gadlnlmhi. [0155] NA pHH21 plasmids were constructed: Alaska NA-T148K/D151E/N245S (found in E4); Alaska NA-G346V; and Alaska NA-T148K/D151E/N245S/G346V (found in E6). Mutant NAs were combined with WT Alaska HA or HY-PR8 backbone. Eggs were inoculated with the same dosage of WT/mutant Alaska viruses and harvested viruses titrated (FIG. 23). NA-T148K/D151E/N245S/G346V mutant virus grew to a higher titer than WT virus but the single mutation G346V did not increase virus growth compared to WT. These results suggested that a combination of G346V and one (or two to three) other mutations, e.g., 3 mutations such as T148K, D151E and N245S, may be important for virus Alaska virus to grow efficiently in eggs. Harvested virus samples with high titer (>5 Log 10 PFU/mL) were sequenced however none had additional mutations in HA and NA.

## REFERENCES

[0156] *Avery's Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics*, 3rd edition, ADIS Press, Ltd., Williams and Wilkins, Baltimore, MD (1987). [0157] Aymard-Henry et al., *Virology: A Practical Approach*, Oxford IRL Press, Oxford, 119-150(1985). [0158] Bachmeyer, *Intervirology*, 5:260 (1975). [0159] Berkow et al., eds., *The Merck Manual*, 16th edition, Merck & Co., Rahway, NJ (1992). [0160] Hatta et al., *Science*, 293:1840 (2001). [0161] Horimoto et al., *J. Virol.*, 68:3120 (1994). [0162] Horimoto et al., *Vaccine*, 24:3669 (2006). [0163] Keitel et al., in *Textbook of Influenza*, eds. Nickolson, K. G., Webster, R. G., and Hay, A. (Blackwell, Oxford), pp. 373-390 (1998). [0164] Kuwahara et al., *Jpn. J. Infect. Dis.*, 71:234 (2018). [0165] Laver & Webster, *Virology*, 69:511 (1976). [0166] Neumann et al., *Adv. Virus Res.*, 53:265 (1999). [0167] Neumann et al., *J. Gen. Virol.*, 83:2635 (2002). [0168] Neumann et al., *J. Virol.*, 71:9690 (1997). [0169] Neumann et al., *Proc. Natl. Acad. Sci. USA*, 96:9345 (1999). [0170] Neumann et al., *Virology*, 287:243 (2001). [0171] Osol (ed.), *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA 1324-1341 (1980). [0172] Sugawara et al., *Biologicals*, 30:303 (2002). [0173] Webby & Webster et al., *Science*, 302:1519 (2003). [0174] Wood & Robertson, *Nat. Rev. Microbiol.*, 2:842 (2004). [0175] World Health Organization TSR No. 673 (1982). [0176] World Health Organization. Confirmed human cases of avian influenza A (H5N1). [http://www.who.int/csr/disease/avian\\_influenza/country/en/index.html](http://www.who.int/csr/disease/avian_influenza/country/en/index.html) [0177] All publications, patents and patent applications are incorporated herein by reference. While in the foregoing specification this invention has been described in relation to certain preferred embodiments thereof, and many details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details described herein may be varied considerably without departing from the basic principles of the invention.

## Claims

1. An isolated recombinant influenza virus comprising a selected NA viral segment encoding a plurality of selected residues or a deletion of residues in NA, wherein the selected NA viral segment does not encode a NA having a threonine at residue 32, does not encode a NA having an aspartic acid at position 147, does not encode a NA having a threonine at position 148, does not encode a NA having an aspartic acid at position 151, does not encode a NA having an asparagine at position 245, does not encode a NA having an asparagine at residue 329, does not encode a NA having a glycine at position 346, does not encode a NA having a histidine at residue 347, or encodes a NA having a deletion of one or more of residues 46 to 50, or any combination thereof, wherein the numbering is based on N2, wherein the recombinant influenza virus has enhanced replication in avian eggs or has a reduction in HA mutations when grown in avian eggs relative to a corresponding influenza virus that has a NA that encodes a threonine at residue 32, does not have a deletion of residues 46 to 50, encodes an aspartic acid at position 147, encodes a threonine at

residue 148, encodes an aspartic acid at residue 151, encodes an asparagine at residue 245, encodes an asparagine at residue 329, encodes a glycine at residue 346, encodes a histidine at residue 347, or any combination thereof.

**2.** The isolated recombinant influenza virus of claim 1 wherein the NA viral segment encodes a NA that has at least 90% amino acid sequence identity to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50 or SEQ ID NO:54.

**3.** The isolated recombinant influenza virus of claim 1 wherein the NA viral segment encodes a N2, N3, N7, or N9.

**4.** The isolated recombinant influenza virus of claim 1 wherein the residue at position 32 is A, I, G, or L; the deletion is a deletion of residues 46 to 50; the residue at position 147 is N or Q; the residue at position 148 is K, R or H; the residue at position 151 is E, N or Q; the residue at position 245 is S, T, I, L, A, N, W, Y, P, V, or G; the residue at position 329 is D or E; the residue at position 346 is S, T, P, Y, W, A, N, I, L, or V; the residue at position 347 is G, Q, S, T, Y, C or W; or any combination thereof.

**5.** The isolated recombinant influenza virus of claim 1 wherein the residue at position 147 is N or Q, the residue at position 329 is D or E, the residue at position 347 is G or Q, or any combination thereof.

**6.** The isolated recombinant influenza virus of claim 1 wherein the residue at position 148 is K, R or H, the residue at position 151 is E, N or Q, the residue at position 245 is S, T, I, L, A, or V, or any combination thereof.

**7.** The isolated recombinant influenza virus of claim 1 wherein the selected NA viral segment does not encode a NA having an aspartic acid at position 147, does not encode a NA having an asparagine at residue 329, does not encode a NA having a histidine, arginine or asparagine at residue 347, or any combination thereof.

**8.** The isolated recombinant influenza virus of claim 1 wherein the selected NA viral segment does not encode a NA having a threonine at position 148, does not encode a NA having an aspartic acid at position 151, does not encode a NA having an asparagine at position 245, does not encode a NA having a glycine at position 346, or any combination thereof.

**9.** The isolated recombinant influenza virus of claim 1 which comprises PA, PB1, PB2, NP, M, and NS viral segments having at least 85% nucleic acid sequence identity to SEQ ID Nos. 24 to 29 or 39 to 44 or encoding a polypeptide having at least 80% amino acid sequence identity to a polypeptide encoded by SEQ ID Nos. 24 to 29 or 39 to 44.

**10.** A method to prepare influenza virus, comprising: contacting a cell with: a vector for vRNA production comprising a promoter operably linked to an influenza virus PA DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus PB1 DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus PB2 DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus HA DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus NP DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus NA DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus M DNA linked to a transcription termination sequence, and a vector for vRNA production comprising a promoter operably linked to an influenza virus NS DNA linked to a transcription termination sequence, wherein the PB1, PB2, PA, NP, NS, and M DNAs in the vectors for vRNA production are from one or more influenza vaccine virus isolates, wherein the NA DNA in the vector for vRNA production encodes a NA having a plurality of selected residues or a deletion of residues, wherein the NA does not encode a NA having a threonine at residue 32, does not encode a NA having an aspartic acid at position 147, does not encode a NA having a threonine at position

148, does not encode a NA having an aspartic acid at position 151, does not encode a NA having an asparagine at position 245, does not encode a NA having an asparagine at residue 329, does not encode a NA having a glycine at position 346, does not encode a NA having a histidine at residue 347, or encodes a NA having a deletion of one or more of residues 46 to 50, or any combination thereof, wherein the numbering for NA residues is that for N2; and a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus PA, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus PB1, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus PB2, and a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus NP, and optionally a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus HA, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus NA, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus M1, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus M2, or a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus NS2; in an amount effective to yield infectious influenza virus.

- 11.** The method of claim 10 wherein the NA has at least 90% amino acid sequence identity to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:48, SEQ ID NO:49, or SEQ ID NO:54.
  - 12.** The method of claim 10 wherein the residue at position 147 is N or Q; the residue at position 329 is D or E; the residue at position 347 is Q, N, S, T, Y, C or W; the residue at position 151 is E, N or Q; the residue at position 148 is K, R or H; the residue at position 245 is S, T, I, L, A, N, W, Y, P, V, or G.
  - 13.** The method of any one of claim 10 wherein the virus comprises PA, PB1, PB2, NP, M, and NS viral segments having at least 85% nucleic acid sequence identity to SEQ ID Nos. 24 to 29 or 39 to 44 or encoding a polypeptide having at least 80% amino acid sequence identity to a polypeptide encoded by SEQ ID Nos. 24 to 29 or 39 to 44.
  - 14.** Isolated virus prepared by the method of claim 10.
  - 15.** A method of immunizing an avian or a mammal, comprising: administering to the avian or the mammal a composition having an effective amount of the virus of claim 1.
  - 16.** The method of claim 15 wherein the composition comprises at least one other different influenza virus.
  - 17.** The method of claim 15 wherein the mammal is a human.
  - 18.** The method of claim 15 wherein the composition is administered intranasally.
  - 19.** The method of claim 15 wherein the composition is administered via injection.
  - 20.** A method comprising passaging the virus of claim 1 in eggs.
-